imatinib mesylate has been researched along with Local Neoplasm Recurrence in 420 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 141 (33.57) | 29.6817 |
| 2010's | 217 (51.67) | 24.3611 |
| 2020's | 62 (14.76) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, YB | 1 |
| Cao, H; Feng, F; Fu, Y; Gao, ZD; Hu, JB; Jie, ZG; Kou, YW; Li, Y; Liu, HJ; Liu, HL; Qian, HR; Qiu, HB; Shen, KT; Sun, XF; Tao, KX; Wu, XJ; Wu, XY; Xu, H; Yang, WC; Zhai, G; Zhang, B; Zhang, J; Zhang, P; Zhou, YB; Zou, XM | 1 |
| Badalamenti, G; Bauer, S; Blay, JY; Brunello, A; Casali, PG; De Pas, T; Dei Tos, AP; Desar, IME; Falkenhorst, J; Fiocco, M; Fumagalli, E; Gasperoni, S; Gelderblom, H; Gennatas, S; Grignani, G; Gronchi, A; Hindi, N; Hohenberger, P; IJzerman, NS; Italiano, A; Joensuu, H; Jones, RL; Le Cesne, A; Martin-Broto, J; Mir, O; Nannini, M; Napolitano, A; Pantaleo, MA; Reichardt, P; Rutkowski, P; Sbaraglia, M; Silletta, M; Spalato Ceruso, M; Steeghs, N; Tonini, G; van Houdt, WJ; Vincenzi, B | 1 |
| Barasoain, I; Castillo, UD; Díaz, JF; Elemento, O; Galletti, G; Giannakakou, P; Goodson, HV; Kita, K; Lu, Y; Madhukar, N; Molina, H; Navarro, EV; RoyChoudhury, A; Sackett, D; Shah, MA; Thakkar, PV | 1 |
| Hong, R; Jung, Y; Kim, SJ; Lee, J | 1 |
| Bang, YH; Kang, S; Kang, YK; Kim, HD; Lee, HE; Ryu, MH | 1 |
| Chiguchi, G; Cho, H; Kataoka, M; Katayanagi, S; Kikuchi, H; Maruyama, T; Nabeshima, K; Sato, S; Takahashi, T | 1 |
| Ando, T; Atsuta, K; Hayashi, M; Isobe, K; Mihara, Y; Nakayama, T | 1 |
| Doki, Y; Eguchi, H; Hirota, S; Kawabata, R; Kurokawa, Y; Makino, T; Motoori, M; Nakajima, K; Nishida, T; Nishikawa, K; Omori, T; Saito, T; Takahashi, T; Tanaka, K; Teranishi, R; Ushimaru, Y; Yamamoto, K; Yamashita, K | 1 |
| Cao, H; Huang, C; Huang, P; Li, Q; Ma, X; Ni, B; Shen, Y; Tu, L; Wang, M; Xia, X; Yang, L; Zhang, Z; Zhao, E; Zhao, W; Zhu, C; Zhuang, C | 1 |
| Cen, Y; Chen, Y; Gong, J; Li, L; Lian, N; Liu, R; Shen, X; Shen, Y; Wan, Q; Wu, X; Wu, Y; Xia, L; Xiao, H; Xu, X; Zhao, R | 1 |
| Åhlen, J; Bränström, R; Haglund de Flon, F; Jalmsell, L; Karlsson, F; Linder-Stragliotto, C; Papakonstantinou, A; Renberg, S; Zhang, Y | 1 |
| Cho, H; Hirota, S; Kagimura, T; Kitagawa, Y; Komatsu, Y; Kondo, M; Kurokawa, Y; Nakahara, Y; Nishida, T; Ozaka, M; Sato, S | 1 |
| Bang, YH; Kang, YK; Kim, HD; Lee, HE; Ryu, MH | 1 |
| Chen, W; Cheng, X; Wu, T | 1 |
| Buljan, M; Crnarić, I; Delaš Aždajić, M; Šitum, M; Vučić, M | 1 |
| Alacacıoğlu, A; Bütün, O; Demirdöver, C; Güç, H; Güç, ZG | 1 |
| Blum, A; Brandstetter, S; Buchstaller, HP; Busch, M; Dorsch, D; Esdar, C; Glaser, N; Grädler, U; Linde, N; Petersson, C; Ruff, A; Schieferstein, H; Sherbetjian, E | 1 |
| Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kawai, K; Masuzawa, T; Murata, K; Nakata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y | 1 |
| Doi, T; Naito, Y; Nishida, T | 1 |
| Duyster, J; Follo, M; Illert, AL; Jilg, S; Jolic, M; Jost, PJ; Peschel, C; Philipp, U; Rassner, M; Scherer, F; von Bubnoff, N; Waldeck, S; Wehrle, J | 1 |
| Bleckman, RF; Bonenkamp, HJJ; Gelderblom, H; IJzerman, NS; Mathijssen, RHJ; Mohammadi, M; Reyners, AKL; Roets, E; Steeghs, N; van Etten, B | 1 |
| Alberti, S; Bellani, V; Bucelli, C; Cattaneo, D; Croci, GA; Iurlo, A; Maronese, CA | 1 |
| Boye, K; Hovig, E; Khelik, K; Meza-Zepeda, LA; Myklebost, O; Nakken, S; Namløs, HM; Vodák, D | 1 |
| Brown, R; Caliskan, PM; Cove, L; David, MP; Dicker, G; Funderburg, A; Gardner, JM; Hoffman, L; Horne, T; Selig, JP | 1 |
| Barysauskas, CM; Demetri, GD; Fletcher, JA; George, S; Kuang, Y; Leal, A; Mariño-Enríquez, A; Morgan, JA; Paweletz, CP; Phallen, J; Serrano, C; Triplett, O; Velculescu, VE; Wagner, AJ | 1 |
| Bonvalot, S; Casali, P; Gronchi, A; Hohenberger, P; Litiere, S; Olungu, C; Rutkowski, P; Stoeckle, E; van Coevorden, F; Wardelmann, E | 1 |
| Giordano, FA; Grimm, M; Groden, C; Hochhaus, A; Hofheinz, R; Sautter, L; Schmieder, K; Tuettenberg, J; Vajkoczy, P; Wenz, F | 1 |
| Deininger, MW; O'Hare, T; Pomicter, AD; Yan, D | 1 |
| Gao, J; Liu, W; Shuai, X; Tao, K; Wang, S; Zeng, X; Zhang, P | 1 |
| Hirano, H; Hirota, S; Iwamoto, H; Katayanagi, S; Katsumata, K; Kawachi, S; Makuuchi, Y; Osakabe, H; Sumi, T; Tsuchida, A; Yokoyama, T | 1 |
| Androulakis, N; Aravantinos, G; Avgerinos, A; Boukovinas, I; Christodoulou, C; Kosmidis, P; Kotsakis, A; Kousidou, O; Michalaki, V; Papandreou, C; Sidiropoulou, V | 1 |
| Bindal, P; Noor, A; Ramirez, M; Vredenburgh, J | 1 |
| Cai, Z; Fu, W; Pu, L; Shen, C; Wang, J; Wang, Y; Yin, X; Yin, Y; Zhang, B | 1 |
| Kashu, N; Kataoka, N; Makimoto, S; Shono, Y; Takami, T; Tomita, M; Yamaguchi, T; Yasuda, K; Yoshitake, H | 1 |
| Akami, T; Hatakeyama, T; Komiyama, S; Mazaki, T; Ogino, S; Sakai, K; Tamai, H; Ueda, Y | 1 |
| Aida, T; Miyazawa, K; Miyoshi, T; Ogasawara, T; Sato, S; Shiobara, M; Suda, K; Wakatsuki, K; Yamazaki, K; Yoshioka, S | 1 |
| Cai, GQ; Liao, GQ; Liu, HL; Liu, S; Liu, WH; Qi, J; Ren, F; Shi, W | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Hou, Y; Jiang, Q; Li, J; Lin, Q; Liu, J; Lu, W; Ma, L; Tao, P; Tong, H; Wang, J; Xue, R; Zhang, G; Zhang, Y | 1 |
| Roth, M; Triche, L; Wells, R; Yarbrough, A; Ying, A | 1 |
| Kitagawa, Y; Takai, S | 1 |
| Adachi, S; Akagi, K; Andou, H; Douno, K; Hirota, M; Imamura, H; Iwazawa, T; Kawase, T; Nagase, H; Noguchi, K; Noura, S; Oshima, K; Taguchi, T; Tamura, Y; Tanida, T | 1 |
| Akamatsu, H; Furukawa, K; Imasato, M; Kado, T; Kishi, K; Mikamori, M; Ohtsuka, M; Saito, T; Suzuki, Y; Tanemura, M | 1 |
| Aydin, E; Erdogan, O; Rencuzogullari, A; Teke, Z | 1 |
| Anwei, X; Jiaxin, L; Kuntang, S; Lei, R; Peiyun, Z; Shanshan, S; Wei, Y; Xiaodong, G; Yingyong, H; Yong, F; Zheng, T; Zhengwen, X | 1 |
| Beck, MY; Kang, YK; Kim, EJ; Lee, MW; Lee, WJ; Park, SR; Ryu, MH | 1 |
| Keung, EZ; Raut, CP; Rutkowski, P | 1 |
| He, YL; Zhang, XH | 1 |
| Gao, XD; Shen, KT; Sun, JY | 1 |
| Athanasou, NA; Gibbons, CLMH; Lips, W; Mastboom, MJL; McCarthy, CL; Mifsud, M; Ng, C; van de Sande, MAJ; van Langevelde, K | 1 |
| Bai, X; Li, Y; Lin, G; Zhou, W | 1 |
| Brosens, LAA; Gertsen, EC; Ruurda, JP; van Boxel, GI; van Hillegersberg, R | 1 |
| Kouyama, M; Nakamitsu, A; Sasaki, M; Shimbara, K; Sugiyama, Y; Takahashi, S; Tazaki, T | 1 |
| Kim, BJ; Kim, HJ; Kim, HS; Kim, JG; Park, JM; Park, JY | 1 |
| Adam, J; Blay, JY; Boilève, A; Brahmi, M; Chamseddine, A; Dufresne, A; Dumont, S; Faron, M; Haddad, V; Honoré, C; Karanian, M; Le Cesne, A; Meeus, P; Mir, O; Nassif, E; Rouleau, E | 1 |
| Adashek, JJ; Chantharasamee, J; Chmielowski, B; Dry, S; Eckardt, MA; Eilber, FC; Singh, AS; Wong, K | 1 |
| Adams, D; Advani, AS; Ali-Osman, F; Carew, JS; Cooper, B; Corrigan, D; Cotta, CV; Elson, P; Fensterl, J; Foster, B; Griffiths, EA; Jia, X; Kalaycio, M; Li, H; Maciejewski, JP; Park, J; Rao, AV; Rizzieri, DA; Rouphail, B; Rush, ML; Sekeres, MA; Sobecks, RM; Tripp, B; Tse, W; Wang, ES | 1 |
| Goto, A; Inaba, K; Inukai, M; Kikuchi, K; Matsuo, K; Nakamura, K; Shibasaki, S; Suda, K; Suzuki, K; Tanaka, T; Tsuru, Y; Uyama, I | 1 |
| Blay, JY; Casali, PG; Duffaud, F; Fumagalli, E; Gelderblom, H; Goldstein, D; Gronchi, A; Hartmann, JT; Hohenberger, P; Italiano, A; Judson, IR; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Martin-Broto, J; Penel, N; Rutkowski, P; Velasco, AP; Wardelmann, E; Zalcberg, JR | 1 |
| Araki, K; Harimoto, N; Hoshino, T; Ishii, N; Kakizaki, S; Kudo, T; Masuda, T; Naganuma, A; Ogawa, T; Ogawa, Y; Shirabe, K; Suzuki, Y; Tateno, K; Tateyama, Y; Uehara, S; Yasuoka, H | 1 |
| Hazama, S; Iida, M; Ioka, T; Kanesada, K; Kimura, S; Matsui, H; Matsukuma, S; Nagano, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tomochika, S; Watanabe, Y; Yoshida, S | 1 |
| Liao, MJ; Lu, T; Wu, YQ; Yang, QB | 1 |
| Fukuoka, T; Iseki, Y; Lee, S; Matsuzuka, S; Miki, Y; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Yoshii, M | 1 |
| Chen, K; Chen, W; Hu, L; Lu, X; Luan, X; Mao, J; Tang, Y; Zhang, J; Zhang, S; Zhang, X; Zheng, X | 1 |
| Billingsley, KG; Corless, CL; Heinrich, MC; Mayo, SC; Sheppard, BC; Sutton, TL; Walker, BS | 1 |
| Chiang, YJ; Feig, BW; Massarweh, NN; Roland, CL; Somaiah, N; Voss, RK | 1 |
| Alcantar, O; Bollag, G; Burton, EA; Carias, H; Chan, K; Chugh, R; Ewing, T; Habets, G; Ibrahim, PN; Inokuchi, K; Lin, J; Marimuthu, A; Matusow, B; Michelson, G; Nespi, M; Patnaik, A; Rezaei, H; Sanftner, L; Severson, PL; Shellooe, R; Shields, AF; Spevak, W; Tap, WD; Tinoco, G; Trent, JC; Tsai, J; Tsang, G; Tsiatis, AC; Wagner, AJ; Wu, G; Zhang, C; Zhang, Y | 1 |
| Mei, X; Qianyi, W; Rui, Z; Xiaoding, S; Xiaoting, W; Yong, W; Yutao, W | 1 |
| Cao, H; Feng, F; Hu, J; Lin, G; Liu, Q; Tao, K; Xia, L; Xiong, Z; Yang, W; Ye, Y; Zhang, B; Zhang, P; Zhao, Y | 1 |
| Aubry, S; Braunstein, C; Chaigneau, L; Delroeux, D; Hubert, P; Kalbacher, E; Marie, B; Meynard, G; Mihai, I; Sirveaux, F | 1 |
| Han, X; Lin, G; Qiu, H; Xu, J | 1 |
| Campiotti, L; Gambacorti-Passerini, C; Grandi, AM; Guasti, L; Piazza, R; Squizzato, A; Suter, MB | 1 |
| Bambara, HA; Lamien/Sanou, A; Ouédraogo Nde, NA; Ouédraogo, MS; Ouédraogo, NA; Tapsoba, GP; Thouraya Chtioui, A; Tiemtoré-Kambou, BM; Traoré, F; Zongo, N | 1 |
| Chen, J; Chen, Z; Shen, C; Tang, S; Yang, J; Yao, Y; Yin, X; Yin, Y; Zhang, B | 1 |
| Mori, M; Nakashima, Y; Nishida, T; Takahashi, T; Tsujinaka, T; Yasui, M | 1 |
| Bertucci, F; Blay, JY; Bompas, E; Bonvalot, S; Bouché, O; Delhorme, JB; Duffaud, F; Gagniere, J; Isambert, N; Meeus, P; Salas, S; Stoeckle, E; Toulmonde, M | 1 |
| Diller, A; Laborie, MV; Seculini Patiño, CE; Tabares, AH | 1 |
| Chen, G; Chu, X; Cui, G; Cui, Q; Dai, Y; Guo, H; Han, G; Hou, Q; Hui, X; Jiang, L; Li, L; Li, Y; Lin, H; Lu, C; Lun, Z; Luo, W; Su, Y; Sun, Z; Wang, A; Wei, Z; Xia, L; Yang, D; Yao, L; Zhang, H; Zhou, Y | 1 |
| Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K | 1 |
| Aguilar, JG; Antonescu, CR; Balachandran, VP; Cavnar, MJ; DeMatteo, RP; Guillem, JG; Keohan, M; Nash, GM; Paty, PB; Singer, S; Tap, WD; Temple, L; Wang, L; Weiser, MR | 1 |
| Ehmke, N; Gopakumar, H; Harrison, S; Sharma, NR; Zelt, C | 1 |
| Chishima, T; Eilber, FC; Elliott, I; Endo, I; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Miyake, K; Miyake, M; Momiyama, M; Murakami, T; Nelson, SD; Russell, T; Singh, A; Zhang, Z | 1 |
| Iwamatsu, K; Kimura, A; Kogure, N; Kuwano, H; Nakazawa, N; Ogata, K; Suzuki, M; Ubukata, Y; Yanai, M; Yanoma, T | 1 |
| Appay, R; Aubert, S; Bouvier, C; Delteil, C; Macagno, N; Magis, Q; Malissen, N; Richard, MA | 1 |
| Büttner, R; Eriksson, M; Hartmann, W; Huss, S; Ihle, MA; Jeske, W; Joensuu, H; Merkelbach-Bruse, S; Reichardt, P; Schildhaus, HU; Sihto, H; Sundby Hall, K; Wardelmann, E | 1 |
| Gao, J; Li, J; Li, Y; Shen, L; Wu, X; Xu, W | 1 |
| Feng, L; Ren, S; Tang, J; Wang, P; Wang, Y; Xu, L; Xu, M; Zhang, M; Zhao, R; Zheng, X | 1 |
| Kivinen, K; Lohi, O; Lund-Aho, T; Lundán, T; Nikkilä, A; Porkka, K; Poukka, M; Raittinen, P | 1 |
| Bruckner, T; Debus, J; Hees, K; Herfarth, K; Jäkel, O; Land, B; Sprave, T; Sterzing, F; Uhl, M; Verma, V | 1 |
| Akgül Babacan, N; Akin Telli, T; Alan, O; Basoglu Tuylu, T; Dane, F; Ercelep, O; Hasanov, R; Kaya, S; Mutis, A; Tanrikulu Simsek, E; Yumuk, PF | 1 |
| Shu, Y; Xu, X; Yang, W; Zhang, X | 1 |
| Doki, N; Fujisawa, S; Harada, H; Imajo, K; Inokuchi, K; Kanda, Y; Kawaguchi, A; Kimura, S; Kobayashi, H; Kojima, K; Komukai, S; Kondo, E; Kondo, T; Kosugi, H; Kosugi, N; Kumagai, T; Kuroda, H; Maeda, Y; Morita, S; Nakao, T; Nawa, Y; Nishida, J; Ogasawara, M; Saito, A; Sakamoto, J; Sakura, T; Shikami, M; Tabe, Y; Ueda, Y; Usuki, K; Yoshida, C | 1 |
| Emoto, S; Hata, K; Hiyoshi, M; Kaneko, M; Kawai, K; Murono, K; Nishikawa, T; Nozawa, H; Sasaki, K; Shuno, Y; Sonoda, H; Tanaka, T | 1 |
| Gao, J; Li, J; Li, Y; Pan, F; Qi, C; Shen, L | 1 |
| Bjerkehagen, B; Boye, K; Hompland, I; Hølmebakk, T; Stoldt, S | 1 |
| Baerlocher, GM; Balleisen, L; Beelen, DW; Bentz, M; Berdel, WE; Bildat, S; Brossart, P; Brümmendorf, TH; Burchert, A; de Wit, M; Dengler, J; Eckart, MJ; Edinger, M; Fabarius, A; Falge, C; Fuchs, R; Gassmann, W; Geer, T; Goebeler, ME; Haferlach, C; Hahn, M; Hänel, M; Hasford, J; Hebart, H; Hehlmann, R; Heim, D; Hertenstein, B; Ho, A; Hochhaus, A; Hossfeld, DK; Kneba, M; Köhne, CH; Kolb, HJ; Krause, SW; Kremers, S; Lauseker, M; Lindemann, HW; Link, H; Mayer, J; Michel, C; Möhle, R; Müller, L; Nerl, C; Neubauer, A; Pfirrmann, M; Saussele, S; Schäfer, E; Schafhausen, P; Scheid, C; Schenk, M; Schlag, R; Schlegel, F; Schlegelberger, B; Spiekermann, K; Stegelmann, F; Thomalla, J; Trümper, L; Verbeek, W; Waller, CF; Wernli, M; Wündisch, T | 1 |
| Bizarro, S; Campilho, F; Campos, A; Cerveira, N; Correia, C; Ferreira, RB; Leite, L; Lisboa, S; Pinho Vaz, C; Santos, R; Teixeira, MR; Torres, L; Vieira, J | 1 |
| Aleshin, AA; Allina, DO; Baranova, MP; Barbara, VS; Kamashev, DE; Kochergina-Nikitskaya, IN; Makovskaia, LA; Poddubskaya, EV; Sekacheva, MI; Suntsova, MV | 1 |
| Beck, M; Chae, H; Kang, YK; Kim, BS; Kim, CW; Kim, JH; Kim, KH; Na, H; Ryu, MH; Yoo, C; Yoo, MW; Yook, JH | 1 |
| Li, K; Shou, CH; Tjhoi, WEH; Yang, WL; Yu, JR | 1 |
| Goto, T; Ishida, R; Ku, Y; Miyashita, M; Muramatsu, S; Sendo, H; Tsukamoto, Y; Yamazaki, T; Yasuda, T | 1 |
| Abella, E; Amigo, ML; Artola, MT; Barba, P; Barrios, M; Bravo, P; Cervera, M; Feliu, E; García, O; García-Belmonte, D; García-Cadenas, I; García-Guiñón, A; Genescà, E; Gil, C; González-Campos, J; Hernández-Rivas, JM; Lavilla, E; Martínez-Carballeira, D; Mercadal, S; Montesinos, P; Moreno, MJ; Novo, A; Ribera, J; Ribera, JM; Serrano, J; Tormo, M; Vives, S | 1 |
| Beck, MY; Kang, YK; Kim, JJ; Ma, JE; Ryu, MH; Yoo, C | 1 |
| Anderson, SK; Brown, PD; Buckner, JC; Dixon, JG; Egorin, MJ; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Jenkins, R; Sarkaria, JN; Schwerkoske, J; Twohy, EL | 1 |
| Boye, K; Hølmebakk, T | 1 |
| Peparini, N | 1 |
| Berger, MG; Boureau, L; Cayssials, E; Charbonnier, A; Coiteux, V; Cony-Makhoul, P; Dubruille, V; Dulucq, S; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Henni, T; Ianotto, JC; Jardel, H; Johnson-Ansah, H; Joly, B; Larosa, F; Legros, L; Lenain, P; Liu, J; Mahon, FX; Martiniuc, J; Nicolini, FE; Rea, D; Rigal-Huguet, F; Rousselot, P; Turlure, P; Varet, B; Villemagne, B; Zunic, P | 1 |
| Banerjee, S; Burgoyne, AM; de la Torre, J; Fanta, PT; Parry, L; Ramamoorthy, S; Scherzer, N; Sicklick, JK; Stuart, E; Wang, Y | 1 |
| Alessandrino, F; Jagannathan, JP; Ramaiya, NH; Tirumani, SH | 1 |
| Agaimy, A; Croner, RS; Haller, F; Hohenberger, W; Köhler, J; Märkl, B; Matzel, K; Meidenbauer, N; Schneider-Stock, R; Spatz, J; Vassos, N | 1 |
| Haas, RL; Kerst, JM; Klomp, HM; van Boven, HH; van Coevorden, F; van der Hage, JA; van Huizum, MA; Wicherts, DA | 1 |
| Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J | 1 |
| Dang, YZ; Gao, J; Li, J; Shen, L | 1 |
| DeMatteo, RP; Demetri, G | 1 |
| Chen, HN; Chen, JP; Chen, ZX; Shen, CY; Yang, HX; Zhang, B | 2 |
| Bachet, JB; Blay, JY; Duffaud, F; Emile, JF; Italiano, A; Landi, B; Laurent-Puig, P; Le Cesne, A; Lévy, P; Safar, V | 1 |
| Gronchi, A; Rutkowski, P | 1 |
| Inokuchi, K; Katagiri, S; Kimura, Y; Mizoguchi, I; Mizuguchi, J; Ohyashiki, JH; Ohyashiki, K; Tauchi, T; Yoshimoto, T | 1 |
| Bauer, S; Bonvalot, S; Bylina, E; Casali, PG; Cats, A; de Wilt, JH; Fiore, M; Fumagalli, E; Gronchi, A; Hohenberger, P; Hoiczyk, M; Kerst, JM; Le Cesne, A; Nguyen, BP; Nyckowski, P; Rutkowski, P; Schöffski, P; Sleijfer, S; Stoeckle, E; Tielen, R; Treckmann, J; van Coevorden, F; van der Graaf, W; Verhoef, C | 1 |
| Fan, WC; Hsieh, JS; Huang, CJ; Yin, TC | 1 |
| Lopez, NE; Sicklick, JK | 1 |
| Beadling, C; Collichio, FA; Corless, CL; Demetri, GD; Ernstoff, MS; Fisher, DE; Flaherty, KT; Fletcher, JA; Friedlander, P; Gajewski, TF; Giobbie-Hurder, A; Gonzalez, R; Heinrich, MC; Hodi, FS; Kim, KB; Lawrence, D; Luke, JJ; Marino-Enriquez, A; O'Day, SJ; Van den Abbeele, AD; Weber, JS; Yap, JT; Zhu, M; Zukotynski, KA | 1 |
| Gelderblom, H; Gray, E; Majer, IM; van den Hout, WB; Verheggen, BG | 1 |
| Doki, N; Kakihana, K; Kobayashi, T; Ohashi, K; Oshikawa, G; Sakamaki, H | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Antonescu, CR; Ballman, KV; Brennan, MF; Corless, C; DeMatteo, RP; Demetri, GD; Kolesnikova, V; Maki, RG; McCarter, MD; Norton, J; Owzar, K; Pisters, PW; von Mehren, M | 1 |
| Biemond, BJ; Cornelissen, JJ; Daenen, SM; Deenik, W; Gussinklo, T; Janssen, JJ; Ossenkoppele, GJ; Petersen, E; Smit, WM; Thielen, N; Valk, PJ; van der Holt, B; van Marwijk Kooy, R; Verhoef, GE | 1 |
| He, D; Hou, Y; Hu, Q; Jiang, D; Liu, J; Liu, Y; Lu, S; Lu, W; Shi, Y; Tan, Y; Xu, C; Zhu, X | 1 |
| Claxton, Z; Malik, V; Mongan, AM; Muldoon, C; O'Toole, D; Ravi, N; Reynolds, JV; Rowley, S | 1 |
| Reid, T | 1 |
| Blay, JY; Joensuu, H; Reichardt, P | 1 |
| Alley, WR; Goetz, JA; Jacobson, SC; Mitra, I; Novotny, MV; Vasseur, JA | 1 |
| Binotto, G; Bonifacio, M; Branca, A; Calistri, E; Fanin, R; Gherlinzoni, F; Guardalben, E; Maino, E; Marin, L; Pizzolo, G; Sancetta, R; Semenzato, G; Tiribelli, M | 1 |
| Aich, RK; Das, D; Deb, AR; Ganguly, S | 1 |
| An, HJ; Kang, YK; Kim, BS; Kim, KH; Oh, ST; Ryoo, BY; Ryu, MH; Sohn, BS; Yook, JH; Yu, CS | 1 |
| Blay, JY; Joensuu, H; Le Cesne, A; Reichardt, P | 1 |
| Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS | 1 |
| Buck, G; Fielding, AK; Foroni, L; Gerrard, G; Goldstone, AH; Lazarus, H; Litzow, MR; Luger, SM; Marks, DI; McMillan, AK; Moorman, AV; Paietta, E; Patel, B; Rowe, JM; Tallman, MS | 1 |
| Dourthe, LM; Heymann, S; Imperiale, A; Sauer, B; Schlund-Schoettel, E | 1 |
| Allgayer, H; Hohenberger, P; Leupold, J; Nowak, K; Rotert, JV | 1 |
| Huang, BT; Tan, Y; Zeng, QC; Zhao, WH | 1 |
| Bassan, R | 1 |
| Bertola, G; Buonadonna, A; Canzonieri, V; Gasparotto, D; Libra, M; Maestro, R; Marzotto, A; Miolo, G; Torrisi, E | 1 |
| Antonescu, CR; Ballman, KV; Blackstein, ME; Blanke, CD; Corless, CL; DeMatteo, RP; Demetri, GD; Heinrich, MC; Kolesnikova, V; Maki, RG; McCarter, MD; Owzar, K; Patel, S; Pisters, PW; von Mehren, M | 1 |
| Al-Batran, SE; Ballman, KV; Bauer, S; DeMatteo, RP; Duyster, J; Eriksson, M; Hall, KS; Hartmann, JT; Hohenberger, P; Joensuu, H; Leinonen, M; Nilsson, B; Pink, D; Ramadori, G; Reichardt, P; Sarlomo-Rikala, M; Schlemmer, M; Schütte, J; Sihto, H; Wardelmann, E | 1 |
| Dai, Y; Gong, H; Jiang, L; Lin, H; Ning, L; Yan, W; Zhang, D; Zhang, M; Zhou, Y | 1 |
| Chen, G; Ding, P; Fang, Y; Jiang, W; Kong, L; Li, L; Lin, J; Lu, Z; Pan, Z; Wan, D; Wang, F; Wu, X; Zhang, R | 1 |
| Chen, L; Liu, L; Liu, Y; Wu, X; Xu, W | 1 |
| Cao, H; Du, CY; He, YL; Jie, ZG; Liang, XB; Shi, YQ; Song, C; Wang, YP; Yan, ZS; Zhou, Y | 1 |
| Ahn, JY; Jeong, JH; Jeong, JW; Kim, KH; Kim, MJ; Park, J; Park, MJ; Park, PW; Seo, JY; Seo, YH | 1 |
| Conley, AP; Gauthier, G; Guerin, A; Keir, CH; Sasane, M; Schwiep, F; Wu, EQ | 2 |
| Cao, H; Tu, L; Wang, CJ; Wang, M; Xu, J; Zhang, ZG; Zhang, ZZ; Zhao, WY | 1 |
| Ahlberg, L; Åström, M; Hägglund, H; Hallböök, H; Hulegårdh, E; Karbach, H; Karlsson, K; Markuszewska, A; Persson, I | 1 |
| Kang, YK; Kim, BS; Kim, CW; Kim, HJ; Kim, KH; Park, SJ; Park, YS; Ryoo, BY; Ryu, MH; Sohn, BS; Yook, JH; Yu, CS | 1 |
| Chung, KM; Lai, EC; Lau, SH; Lau, WY | 1 |
| Bender, HU; Blau, IW; Burdach, S; Burmeister, T; Hofmann, WK; Kiewe, P; Kolb, HJ; Neumann, M; Notter, M; Pursche, S; Reinwald, M; Schleyer, E; Thiel, E | 1 |
| Kobayashi, H; Sugihara, K | 1 |
| Aihara, R; Ando, H; Fukuchi, M; Haga, N; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Ohno, T; Ojima, H; Suzuki, M; Toyomasu, Y; Uchida, N; Yokobori, T | 1 |
| Kristensen, TK; Møller, MB; Rathe, M; Schomerus, E; Wehner, PS | 1 |
| Huang, KE; Jia, J; Li, X; Pan, SD; Pan, YL; Tao, DY; Zheng, S; Zheng, XL; Zhou, Y | 1 |
| Anjum, R; Bauer, S; Clackson, T; Eilers, G; Fletcher, JA; Garner, AP; Gozgit, JM; Heinrich, MC; Ketzer, J; Kohlmann, A; Ning, Y; Rivera, VM; Schrock, A; Serrano, C; Song, Y; Vodala, S; Wang, F; Wardwell, S; Zhou, T; Zhu, M | 1 |
| Balachandran, VP; DeMatteo, RP | 1 |
| Antonarakis, ES; Lin, J; Suzman, DL; Zahurak, ML; Zhou, XC | 1 |
| Gauthier, G; Guerin, A; Keir, CH; Sasane, M; Wu, EQ; Zhdavana, M | 1 |
| Benchakroun, N; Benider, A; Bouchbika, Z; Dao, A; Jabir, H; Jouhadi, H; Sahraoui, S; Taleb, A; Tawfiq, N | 1 |
| Chen, H; Chen, J; Chen, Z; Shen, C; Yin, Y; Zhang, B | 1 |
| Andres, R; Calabuig, S; Casado, A; Cruz, J; De Juan, A; Del Muro, JG; Fra, J; Garcia-Albeniz, X; Lainez, N; Lopez-Pousa, A; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Poveda, A; Redondo, A; Rubió-Casadevall, J; Sevilla, I; Valverde, C | 1 |
| Fang, Y; Gao, X; Hou, Y; Li, H; Ling, J; Qin, J; Qin, X; Shen, K; Shu, P; Sun, Y; Xue, A | 1 |
| Burchert, A; Eigendorff, E; Hehlmann, R; Hochhaus, A; Hoffmann, J; Inselmann, S; Kostrewa, P; Metzelder, SK; Müller, MC; Neubauer, A; Saussele, S; Schütz, C; Sohlbach, K; Ziermann, J | 1 |
| Becq, J; Bentley, D; Benz, SC; Birkbak, NJ; Brada, M; Dietrich, PY; Eklund, AC; Favero, F; Forshew, T; Gerlinger, M; Grocok, RJ; Gutteridge, A; Humphray, S; Kingsbury, Z; McGranahan, N; Peden, JF; Roger, S; Rowan, A; Salm, M; Sanborn, JZ; Spencer-Dene, B; Stamp, G; Swanton, C; Szallasi, Z | 1 |
| Dang, Y; Gao, J; Li, J; Li, Y; Shen, L; Zou, J | 1 |
| Kang, YK; Kim, BS; Koh, YW; Park, HJ; Park, YS; Ryoo, BY; Ryu, MH; Yoo, C; Yook, JH | 1 |
| Joensuu, H; Maki, RG; Martin-Broto, J; Nishida, T; Reichardt, P; Schöffski, P | 1 |
| Alwayn, I; Cimen, S; Guler, S; Panek, R | 1 |
| Chang, SC; Chen, YY; Cheng, CT; Chiang, KC; Liao, CH; Liu, CT; Ma, MC; Tsai, CY; Wang, SY; Yeh, CN; Yeh, TS | 1 |
| He, ZD; Huang, XE; Zhou, JN | 1 |
| Barrios, CH; Blackstein, ME; Blay, JY; Casali, PG; Chacon, M; Gu, J; Kang, YK; Nishida, T; Purkayastha, D; Reichardt, P; Woodman, RC | 1 |
| Blay, JY; Hirota, S; Kang, YK; Kitagawa, Y; Nishida, T | 1 |
| Casali, PG; Gronchi, A; Hindi, N; Messina, A; Morosi, C; Palassini, E; Pilotti, S; Radaelli, S; Stacchiotti, S; Tamborini, E | 1 |
| Blay, JY; Levard, A | 1 |
| Ao, Q; Fei, Y; Wang, G; Wang, Y; Zhu, P | 1 |
| Adenis, A; Blay, JY; Broto, JM; Casali, PG; Dei Tos, AP; Duffaud, F; Fumagalli, E; Gelderblom, H; Goldstein, D; Gronchi, A; Hartmann, JT; Hohenberger, P; Italiano, A; Judson, IR; Kotasek, D; Le Cesne, A; Litière, S; Marréaud, S; Poveda Velasco, A; Rutkowski, P; van der Graaf, WT; Zalcberg, JR | 1 |
| Ding, Y; Wen, G; Xu, L; Zhao, L | 1 |
| Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S | 1 |
| Bando, E; Kawamura, T; Makuuchi, R; Miki, Y; Nakajima, T; Sugisawa, N; Tanizawa, Y; Terashima, M; Tokunaga, M | 1 |
| Kaczmarek, Ł; Kotlarz, A; Markowicz, S; Miłoszewska, J; Przybyszewska, M; Pyśniak, K; Swoboda, P; Szczepek, W | 1 |
| Alvegård, T; Bauer, S; Cameron, S; Eriksson, M; Hohenberger, P; Joensuu, H; Leinonen, M; Reichardt, A; Reichardt, P; Rejmyr Davis, M; Schütte, J; Sundby Hall, K | 1 |
| Chen, P; Li, Q; Ma, L; Røe, OD; Sun, L; Tao, R; Zhang, J; Zhi, X; Zhou, J | 1 |
| Ame, S; Bennaceur-Griscelli, A; Bonnet, ML; Bourhis, JH; Chomel, JC; Guerci-Bresler, A; Legros, L; Marfaing-Koka, A; Rea, D; Rousselot, P; Sloma, I; Sorel, N; Turhan, AG | 1 |
| Fujita, J; Hirota, S; Masuzawa, T; Nishida, T; Sato, S; Takagi, M; Takahashi, T; Tsujinaka, T; Yamamoto, K; Yamashita, Y | 1 |
| Mathew, J; Natesh, B; Rajan, R; Raviram, S; Sindhu, RS; Valappil, FK | 1 |
| Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S | 1 |
| Hompes, D; Rutkowski, P | 1 |
| Cao, H; Wang, M | 1 |
| Shen, C; Zhang, B | 1 |
| Chen, T; Chen, Z; Feng, X; Li, G; Li, Y; Qiu, H; Sun, X; Tao, K; Yu, J; Zhang, P; Zhou, Z | 1 |
| Dong, Z; Gao, J; Gong, J; Li, J; Li, Y; Shen, L; Wang, X | 1 |
| Lei, C; Liu, L; Wang, H; Wang, Q | 1 |
| Fu, Y; Guo, L; Hao, H; Yang, G; Zhang, X | 1 |
| Allaoui, M; Elm'hadi, C; Errihani, H; Ichou, M; Khmamouche, MR; Mahtat, E; Messaoudi, N; Oukabli, M; Tanz, R; Toreis, M | 1 |
| Adachi, S; Hiramatsu, H; Horibe, K; Ishii, E; Kaneko, T; Kato, I; Kato, K; Kato, M; Kawasaki, H; Kodama, Y; Manabe, A; Matsumoto, K; Mizutani, S; Oda, M; Saito, AM; Sano, H; Sato, A; Shimada, H | 1 |
| Arellano, M; Bodó, I; Chen, Z; El-Rassi, F; Heffner, LT; Hill, B; Jillella, A; Khoury, HJ; Kim, A; Kong, JH; Kota, VK; Langston, AA; Winton, EF | 1 |
| de Wilt, JH; den Bakker, MA; Eggermont, AM; Mearadji, A; Sleijfer, S; van Geel, AN; Verhoef, C; Verweij, J | 1 |
| Heger, U; Lordick, F; Weitz, J | 1 |
| Klein-Szanto, AJ; Lee, RB; Miner, Z; Schilder, RJ; Senterman, MK; Shaw, TJ; Sill, MW; Vanderhyden, BC | 1 |
| Hamada, M; Horimi, T; Iwata, J; Nagata, Y; Nasu, Y; Ozaki, K; Tsuji, A | 1 |
| Conneally, E; Langabeer, S; McCann, SR; O'Connor, LM | 1 |
| Aklan, T; Hoeffken, K; Lemm, D; Mentzel, T; Muegge, LO; Schultze-Mosgau, S; Thorwarth, M | 1 |
| Brandes, AA; Clement, PM; Coudert, B; Dittrich, C; Frenay, M; Fumoleau, P; Gorlia, T; Heinrich, MC; Kros, JM; Lacombe, D; Rampling, R; Raymond, E; Stupp, R; van den Bent, MJ | 1 |
| Hur, H; Jee, SB; Jeon, HM; Jung, SE; Kim, W; Park, AR | 1 |
| Hirota, S; Kubota, T; Minami, M; Nishida, T; Otani, Y; Shimada, Y; Sugino, Y; Takahashi, F; Yamamura, Y; Yanagisawa, A | 1 |
| Camci, C; Sevinc, A | 1 |
| Asano, S; Dairaku, N; Hiwatashi, N; Ikeya, S; Kojima, Y; Koshita, S; Kusano, M; Nakayama, H; Ojima, T; Shimada, N; Sugai, Y; Yamagiwa, T; Yokoyama, A | 1 |
| Bonello, L; Bosco, M; Daniele, L; Filosso, P; Macri', L; Mussa, B; Prunotto, M; Rossi, G; Sapino, A; Schirosi, L | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N; Rios, MB; Shan, J; Verstovsek, S; Wierda, WG | 1 |
| Autzinger, E; Azizi, A; Czech, T; Gruber-Olipitz, M; Haberler, C; Jones, N; Peyrl, A; Prayer, D; Slavc, I | 1 |
| Aghajanian, C; Hensley, ML; Iasonos, A; Juretzka, M; Konner, J; Leitao, M; Park, K; Sabbatini, P; Soslow, R; Tew, W | 1 |
| Han, H; Wang, YH; Yu, YY | 1 |
| Andersen, BL; Braendstrup, K; Hokland, P; Mikkelsen, LS; Nyvold, CG; Ommen, HB; Ostergaard, M; Stentoft, J | 1 |
| DeMatteo, RP; Kingham, TP | 1 |
| Höffken, K; Lemm, D; Mentzel, T; Mügge, LO | 1 |
| Irvine, DA; Shepherd, JD | 1 |
| Buck, G; Dewald, G; Durrant, IJ; Fielding, AK; Foroni, L; Franklin, IM; Goldstone, AH; Lazarus, HM; Litzow, MR; Luger, SM; Marks, DI; McMillan, AK; Moorman, AV; Paietta, E; Richards, SM; Rowe, JM; Tallman, MS; Wiernik, PH | 1 |
| Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Deangelis, LM; Di Tomaso, E; Drappatz, J; Egorin, MJ; Fine, HA; Fink, K; Jain, RK; Kesari, S; Lamborn, KR; Ligon, KL; Mehta, M; Norden, AD; Prados, MD; Robins, HI; Stiles, CD; Wen, PY; Yung, WK | 1 |
| Kim, DK; Kim, YH; Lee, HJ; Park, SI | 1 |
| Luketich, JD; Pennathur, A | 1 |
| Clohisy, DR; Frolich, JW; Manivel, JC; Skubitz, KM | 1 |
| Bachmann, K; Bogoevski, D; Izbicki, J; Kaifi, J; Kohrs, D; Reichelt, U; Schurr, P; Vashist, Y; Yekebas, E | 1 |
| Bartels, U; Baruchel, S; Bouffet, E; Egorin, MJ; Fryer, C; Gammon, J; Halton, J; Hawkins, C; Hukin, J; Martinho, O; Odame, I; Portwine, C; Reis, RM; Sharp, JR; Stempak, D; Strother, D | 1 |
| Aoyama, T; Fujii, K; Fujisawa, J; Ishikawa, Y; Kawamoto, M; Masuda, M; Matsukawa, H; Rino, Y; Saeki, H; Samejima, J | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kikuchi, S; Kokuba, Y; Kubota, T; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Taniguchi, H | 1 |
| Chang, I; Choi, D; Kim, KM; Lee, JY; Lee, WJ; Sohn, TS; Yoo, EY | 1 |
| Dresemann, G; Engel, E; Fluge, O; Heinrich, B; Hosius, C; Karup-Hansen, A; Krex, D; Mayer-Steinacker, R; Mehdorn, M; Nikolova, Z; Nowak, A; Olver, IN; Parker, R; Rosenthal, MA; Schleyer, E; Sieder, C; Sorenson, G; Steinbach, JP; Wagner, W; Wedding, U; Weller, M | 1 |
| Brodowicz, T; Kühr, T | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Dundamadappa, SK; Karam, AR; Shankar, S; Stay, RM; van Sonnenberg, E | 1 |
| Bartal, A; Bocs, K; Hitre, E; Langmár, Z; Liszkay, G; Mátrai, Z; Orosz, Z; Plotár, V; Rényi Vámos, F; Sávolt, A; Székely, J; Tóth, L | 1 |
| Anagnostou, E; Christopoulos, C; Dedemadi, G; Emile, JF; Georgoulis, G; Kontopanos, D; Morphopoulos, G | 1 |
| IMAHASHI, N; MIYAMURA, K; NISHIWAKI, S; OZAWA, Y; TOKUNAGA, M; YANAGISAWA, M | 1 |
| Hou, J; Hou, YY; Liu, JL; Lu, SH; Qin, J; Shen, KT; Sun, YH; Tan, YS; Zhou, Y | 1 |
| Egawa, Y; Futami, K; Higashi, D; Hirano, K; Ishibashi, Y; Iwashita, A; Maekawa, T; Oshige, K; Ota, A; Shimomura, T; Tomiyasu, T; Watanabe, Y | 1 |
| Al-Refaie, WB; Ansel, H; Armstrong, LH; Askari, S; Dudeja, V; Gupta, P | 1 |
| Oka, M; Sakamoto, K; Tsutsui, M; Yoshino, S | 1 |
| Patel, SR; Pisters, PW | 1 |
| Engel, JM; Onitilo, AA | 1 |
| Hou, J; Hou, YY; Lu, SH; Qi, WD; Qin, J; Sun, YH; Tan, YS; Xu, C | 1 |
| Alvarez, RD; Birrer, MJ; Boggess, JF; Darcy, KM; Elias, KM; Hoffman, JS; Huh, WK; Long, HJ; O'Malley, DM; Sill, MW | 1 |
| Giaccone, G; Hogendoorn, PC; Rajan, A; Ruijter, R; Smit, E; van Groeningen, C | 1 |
| Aprile, L; Bocchia, M; Chitarrelli, I; Defina, M; Gozzetti, A; Ippoliti, M; Lauria, F; Rondoni, M | 1 |
| Cheng, JW; Hou, YY; Lu, SH; Tan, YS; Wang, H; Xu, ST; Zheng, RH | 1 |
| Eisenberg, B; Hohenberger, P | 1 |
| Blank, SD; Butrynski, JE; Corless, CL; Dressel, DM; Ebrahim, KS; Heinrich, MC; Hornick, JL; Long, KB | 1 |
| Apperley, JF; Cross, NC; Melo, JV; Score, J; Sobrinho-Simões, M; Wilczek, V | 1 |
| Hou, M; Jiang, M; Yang, Y; Zhou, L; Zhu, J | 1 |
| Blay, JY; Demetri, GD; Dumez, H; Hollaender, N; Jappe, A; Morgan, JA; Ray-Coquard, I; Reichardt, P; Schöffski, P | 1 |
| Bachmann, K; Brandl, S; Izbicki, JR; Kaifi, JT; Kunkel, M; Rawnaq, T; Sauter, G; Simon, R; Zander, H | 1 |
| Dresemann, G; Hasselblatt, M; Jarvius, M; Joensuu, H; Lindh, MB; Nistér, M; Nupponen, NN; Ostman, A; Paulsson, J; Paulus, W; Puputti, M; Söderberg, O; von Deimling, A | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Jayanthi, NV | 1 |
| Karamitopoulou, E; Karatzas, T; Machairas, A; Machairas, N; Misiakos, EP; Tsapralis, D | 1 |
| Bollu, VK; Coombs, JH; Rubin, JL; Sanon, M; Taylor, DC | 1 |
| Andreopoulou, E; Blank, S; Borgato, L; Boyd, L; Curtin, J; Levinson, B; Muggia, F; Pothuri, B; Safra, T; Tiersten, A | 1 |
| Bruce, I; Ghosal, N; Hastings, D; Homer, J; Julyan, P; Mais, K; Ryder, WD; Shenjere, P; Slevin, NJ; Ward, T | 1 |
| Broelsch, CE; Frilling, A; Grabellus, F; Kronenberger, R; Li, J; Malago, M; Schleyer, E; Testa, G | 1 |
| Eisenberg, BL; Smith, KD | 1 |
| George, S; Trent, JC | 1 |
| Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK | 1 |
| Agaimy, A; Daniels, M; Evert, M; Lasota, J; Lüders, P; Miettinen, M; Müller, G; Pelz, AF; Röpke, A; Schneider-Stock, R; Schulz, HU; Wieacker, P | 1 |
| Ganjoo, KN; Patel, S | 1 |
| Raut, CP; Winer, JH | 1 |
| Hao, XS; Huang, H; Li, H; Liang, H; Ren, XB; Zhan, ZL | 1 |
| Kamiya, K; Kikuchi, H; Konno, H; Miyazaki, S; Ohta, M; Sakaguchi, T; Setoguchi, T; Yamamoto, M | 1 |
| Kochatkov, AV; Kolygin, AV; Konstantinova, MM; Korolev, SV; Kriger, AG; Makeeva-Malinovskaia, NIu | 1 |
| Durie, N; Kesterson, J; Lele, S; Mhawech-Fauceglia, P; Syriac, S | 1 |
| Clarke, S; Cooney, J; O'Reilly, J; Romeo, G | 1 |
| Abraham, I; De Geest, S; De Grève, J; Dirix, L; Duck, L; Focan, C; Forget, F; Joosens, E; Macdonald, K; Mazzeo, F; Muermans, K; VAN Lierde, MA | 1 |
| Cooper, K; Hanson, JA; Trent, JC; Yang, D | 1 |
| Besson, C; Darné, C; Delomas, T | 1 |
| Ando, K; Kakeji, Y; Kojima, A; Maehara, Y; Morita, M; Oki, E; Saeki, H; Sugiyama, M; Taketomi, A; Tsujitani, S; Yamamoto, H; Yamashita, Y; Zhao, Y | 1 |
| Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY | 1 |
| Grijuela, B; Guadalupi, V; Martinelli, F; Raspagliesi, F | 1 |
| Liang, J; Liu, ZM; Yu, Z | 1 |
| Bae, HI; Baek, JH; Bang, YJ; Choi, J; Chung, IJ; Im, SA; Kang, HJ; Kang, YK; Kim, JG; Kim, KM; Kim, WH; Kwon, HC; Lee, JH; Lee, KE; Lee, KH; Park, SH; Park, YS; Ryoo, BY; Ryu, MH; Shin, DB; Song, HS | 1 |
| Blanke, CD; Demetri, GD; Eisenberg, BL; Heinrich, MC; Hoffman, JP; Kane, JM; Okuno, S; von Mehren, M; Wang, D; Watson, JC; Zhang, Q | 1 |
| Gronchi, A; Raut, CP | 1 |
| Binckebanck, A; Brück, P; Dührsen, U; Giagounidis, A; Hoelzer, D; Lange, T; Maier, J; Ottmann, OG; Pfeifer, H; Schmalzing, M; Schmidt, A; Serve, H; Stelljes, M; Wassmann, B; Wunderle, L; Wystub, S | 1 |
| Deneve, J; Gonzalez, RJ; Han, D | 1 |
| Chan, SW; Chiang, MH; Lai, HC; Lee, WL; Liu, TJ; Su, CS; Ting, CT | 1 |
| Andrew, DR; Leeder, P; MacGoey, P; McCulloch, T; Parsons, SL; Reece-Smith, AM; Shah, MA | 1 |
| Schmidt, C | 1 |
| Bamboat, ZM; Dematteo, RP | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Branham, D; Broaddus, RR; Coleman, RL; Gershenson, DM; Levenback, CF; Noguera, IR; Ramirez, PT; Sood, AK; Sun, CC | 1 |
| Ahn, KW; Akpek, G; Aljurf, M; Artz, A; Cahn, JY; Cairo, M; Chen, YB; Cooper, B; de Lima, M; Deol, A; Giralt, S; Gupta, V; Khoury, HJ; Kohrt, H; Lazarus, HM; Lewis, I; Olsson, R; Pedersen, TL; Pidala, J; Pulsipher, M; Savani, BN; Seftel, M; Socié, G; Tallman, M; Ustun, C; Vij, R; Vindeløv, L; Warlick, E; Weisdorf, D | 1 |
| Cho, J; Kang, GH; Kim, KM; Park, J; Shim, YM | 1 |
| Al-Batran, SE; Alvegård, T; Bauer, S; Bono, P; Duyster, J; Eriksson, M; Hartmann, JT; Hohenberger, P; Joensuu, H; Kallio, R; Leinonen, M; Monge, OR; Nilsson, B; Pink, D; Ramadori, G; Reichardt, P; Sarlomo-Rikala, M; Schlemmer, M; Schütte, J; Sihto, H; Sundby Hall, K; Vehtari, A; Wardelmann, E | 1 |
| Essodegui, F; Hermas, S; Hissane, EM; Mahdaoui, S; Noun, M; Oubaid, B; Samouh, N | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH; Zhang, YY; Zhao, XY | 1 |
| Alaggio, R; Bisogno, G; Cecchetto, G; Cheng, L; d'Amore, ES; Dall'Igna, P; Martignoni, G; Sperlì, D | 1 |
| Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C | 1 |
| Antonescu, CR; Ballman, KV; Blanke, CD; Brennan, MF; DeMatteo, RP; Demetri, GD; Maki, RG; McCall, L; McCarter, MD; Ota, DM; Pisters, PW; von Mehren, M | 1 |
| Cubedo, R; Quintero, CB | 1 |
| Ballesteros, J; Pulido, EG; Riquelme, A; Vaz, MÁ | 1 |
| del Muro, XG; López, RL | 1 |
| Bonastre, MT; Izquierdo, ME | 1 |
| Chan, M; Choong, A; Chu, S; Chuah, C; Goh, YT; Hwang, W; Koh, M; Lim, TJ; Linn, YC; Loh, Y; Ng, HJ; Niam, M; Suck, G; Yong, HX | 1 |
| Athanasou, NA; Bradley, KM; Dijkstra, PD; Gelderblom, H; Gibbons, CL; Hassan, AB; Hogendoorn, PC; Kroep, JR; Nout, RA; van de Sande, MA; van der Heijden, L; van Rijswijk, CS | 1 |
| Bonenkamp, JJ; de Wilt, JH; Reyners, AK; Tielen, R; van Coevorden, F; van der Graaf, WT; van Etten, B; Verhoef, C | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Aricò, M; Biondi, A; Campbell, M; Castor, A; De Lorenzo, P; Escherich, G; Gandemer, V; Li, CK; Lucchini, G; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stary, J; Valsecchi, MG; Vora, A | 1 |
| Gronchi, A; Hohenberger, P; Jakob, J; Mussi, C; Negri, T; Ronellenfitsch, U; Wardelmann, E | 1 |
| Cao, X; Chen, Y; Luo, Z; Shi, Y; Wang, C; Wang, J; Zhang, R; Zheng, B | 1 |
| Chang, HM; Im, SA; Jung, KH; Kang, BW; Kang, WK; Kang, YK; Kim, TW; Lee, JL; Oh, DY; Park, SR; Ryu, MH | 1 |
| Glauche, I; Hehlmann, R; Hochhaus, A; Horn, M; Loeffler, M; Müller, MC; Roeder, I | 1 |
| Llombart, B; López Guerrero, JA; Monteagudo, C; Sanmartín, O; Serra-Guillén, C | 1 |
| Ando, T; Hosokawa, A; Kajiura, S; Nakata, K; Saito, S; Sugiyama, T | 1 |
| Przybył, J; Rutkowski, P; Zdzienicki, M | 1 |
| Amoroso, L; Calafiore, L; Castellano, A; Corrias, MV; Della Casa Alberighi, O; Dominici, C; Garaventa, A; Haupt, R; Luksch, R; Podda, M; Zanazzo, G | 1 |
| Gorre, ME; Kuriyan, J; Nagar, B; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP | 1 |
| Berger, U; Corbin, AS; Cross, NC; Druker, BJ; Gschaidmeier, H; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; La Rosée, P; Lahaye, T; Müller, MC; Schoch, C | 1 |
| Demetri, GD | 1 |
| Chander, S; Lay Ergun, E; Shields, AF | 1 |
| Chmelik, P; Felix, R; Gaffke, G; Hohenberger, P; Jost, D; Pink, D; Reichardt, P; Schlecht, I; Schneider, U; Stroszczynski, C | 1 |
| Bányai, A; Barta, A; Dolgos, J; Gopcsa, L; Halm, G; Pálóczi, K | 1 |
| Aichele, O; Brümmendorf, T; Denzlinger, C; Kanz, L; Kröber, SM; Schittenhelm, M | 1 |
| Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; König, H; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Petzold, A; Schoch, C; Weisser, A | 1 |
| Brück, P; Gehrke, B; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Petershofen, EK; Pfeifer, H; Scheuring, UJ; Wassmann, B | 1 |
| Bandini, G; Byrne, J; Clark, RE; Deininger, M; Fischer, T; Lipton, J; Michallet, M; Niederwieser, D; Olavarria, E; Ottmann, OG; Siegert, W; Ullmann, A; Vitek, A; Wassmann, B | 1 |
| Bacigalupo, A | 1 |
| Hart, J; Langerman, A; Posner, MC; Ryan, CW; Swiger, S; Wu, PC | 1 |
| Baars, A; Pinedo, HM | 1 |
| Dimitrijevic, S; Dunlop, D; Fischer, B; Fischer, T; Fletcher, C; Hornick, J; Johnson, BE; Kowalski, MO; Le Chevalier, T; Rischin, D; Salgia, R; Sayles, D; Silberman, S | 1 |
| Au, WY; Ho, WK; Hon, C; Kwok, AK; Lie, AK; Ng, WM; Shek, TW | 1 |
| Cunningham, SC; Shibata, D; Volpe, C | 1 |
| Gayed, I; Iyer, R; Johnson, M; Macapinlac, H; Podoloff, D; Swanston, N; Vu, T | 1 |
| Dietrich, CG; Gartung, C; Geier, A; Maintz, C; Matern, S; Siewert, E; Tietze, L | 1 |
| Amabile, M; Baccarani, M; Gaitani, S; Malagola, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Soverini, S; Visani, G | 1 |
| Blay, JY; Boillot, O; Bompas, E; Bringuier, PP; Dumortier, J | 1 |
| Joensuu, H; Kindblom, LG | 1 |
| Gebauer, B; Hohenberger, P; Reichardt, P; Wardelmann, E | 1 |
| Bruzzone, R; Frassoni, F; Fugazza, G; Gatti, AM; Gobbi, M; Grasso, R; Miglino, M; Quintino, S; Sessarego, M | 1 |
| Dieckmann, K; Fakhrai, N; Hainfellner, J; Marosi, C; Nemeth, A; Neophytou, P; Prayer, D | 1 |
| Rytting, ME; Wierda, WG | 1 |
| Juan, MB; López-Andújar, R; Mir, JP; Moya, AH; Orbis, FC; Pareja, EI; Rayón, M; Sanjuan, FR; Serralta, AS; Vila, JC | 1 |
| Bonnet, ML; Bourhis, J; Deutsch, E; Frascogna, V; Khanfir, K; Maggiorella, L; Turhan, AG; Wen, B | 1 |
| Baba, M; Hiramatsu, Y; Kamiya, K; Kanda, T; Kikuchi, H; Kondo, K; Konn, H; Nakamura, S; Ohashi, M; Ohta, M; Sugimura, H; Tanaka, T; Yamamoto, M | 1 |
| Chehal, A; El Hajj, II; El Saghir, NS | 1 |
| Dushkin, H; Schilder, RJ | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Riehm, B; Schoch, C; Schwindel, U | 1 |
| Armbrust, T; Füzesi, L; Gunawan, B; Langer, C; Ramadori, G; Schindler, CG | 1 |
| Jin, ML; Shen, L | 1 |
| Azzoli, CG; Crapanzano, JP; Dunne, M; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Rizvi, N; Tyson, L | 1 |
| Antonescu, CR; Besmer, P; DeMatteo, RP; Eisenstat, J; Greco, AM; LaQuaglia, MP; Maki, RG; Prakash, S; Sarran, L; Socci, N; Wexler, LH | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jelinek, J; Kantarjian, HM; Morris, G; Talpaz, M; Verstovsek, S | 1 |
| Alexis, JB; Lutzky, J; Martinez, AE | 1 |
| Adjei, AA; Aubry, MC; Dy, GK; Jett, JR; Langdon, RM; Mandrekar, SJ; Miller, AA; Morton, RF; Schild, SE | 1 |
| Blanke, CD; Sanborn, RE | 1 |
| Abruzzo, L; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Rios, MB; Verstovsek, S | 1 |
| Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Igarashi, T; Lundqvist, A; Rezvani, K; Savani, BN; Srinivasan, R; Takahashi, Y | 1 |
| Bodurka, DC; Broaddus, RR; Burke, TW; Coleman, RL; Gershenson, DM; Kavanagh, JJ; Levenback, CF; Wolf, JK | 1 |
| Iwazawa, T; Katsushima, S; Matsui, S; Monden, T; Nakano, Y; Ohnishi, T; Okamoto, S; Takemoto, H; Tono, T; Yano, H | 1 |
| Antoni, C; Erk, JU; Haroske, G; Jacobasch, L; Ludwig, K; Stelzner, S | 1 |
| Benjamin, RS; Blanke, CD; Blay, JY; Bonvalot, S; Eisenberg, B | 1 |
| Dziewirski, W; Grzesiakowska, U; Krawczyk, M; Nasierowska-Guttmejer, A; Nowecki, Z; Nyckowski, P; Ruka, W; Rutkowski, P | 1 |
| André, S; Barata, A; Cravo, M; Francisco, I; Nobre-Leitão, C; Salazar, M; Venâncio, J | 1 |
| Kleinschmidt-Demasters, BK; Lillehei, KO; Seinfeld, J; Tayal, S | 1 |
| Ahlman, H; Andersson, J; Bümming, P; Kindblom, LG; Meis-Kindblom, JM; Nilsson, B | 1 |
| Hagiwara, A; Kin, S; Miyagawa, K; Nakase, Y; Nakashima, S; Sagara, Y; Sakakura, C; Soga, K; Yamagishi, H; Yamaoka, N; Yoshikawa, T | 1 |
| McArthur, GA | 1 |
| Choi, WS; Chung, HS; Kim, SD; Kim, SH; Lim, DJ; Park, JY | 1 |
| Hanada, N; Inoue, K; Kawamura, Y; Osako, T; Taneda, T; Yoshida, Y | 1 |
| Fong, K; Fong, L; Lin, AM; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V | 1 |
| Kashimura, H; Kobayashi, K; Koyama, T; Marushima, H; Mitsumori, N; Nimura, H; Odaira, H; Yanaga, K | 1 |
| Blanke, CD; Schnadig, ID | 1 |
| Bi, JW; Chen, DD; Ding, KF; Gu, J; Li, R; Lu, HS; Lu, YF; Shao, YF; Shi, YQ; Sun, YH; Wan, DS; Wang, PZ; Wu, XT; Yu, JR; Zhan, WH; Zhang, XH; Zou, XM | 1 |
| Bonvalot, S; Chami, L; Lamuraglia, M; Lassau, N; Le Cesne, A; Leclère, J; Roche, A; Terrier, P | 1 |
| Andtbacka, RH; Benjamin, RS; Burgess, MA; Chen, LL; Cormier, JN; Feig, BW; Hunt, KK; Ng, CS; Patel, SR; Pisters, PW; Pollock, RE; Raymond, K; Scaife, CL; Trent, J | 1 |
| Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Kato, C; Miyamura, K; Sasaki, T; Sugawara, T; Tomiya, Y; Yamada, M | 1 |
| Bidoli, P; Casali, PG; Casieri, P; Miselli, F; Negri, T; Orsenigo, M; Piacenza, C; Pierotti, MA; Pilotti, S; Stacchiotti, S; Tamborini, E | 1 |
| Fanucchi, M; Folpe, A; Guiteau, J; Kooby, DA; Staley, CA | 1 |
| Ban, S; Fujimura, M; Hirose, T; Ishihara, O; Mitsuhashi, T; Nakayama, M; Ogawa, F; Sakurai, S; Shimizu, M; Shimizu, Y | 1 |
| Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR | 1 |
| Ikeda, E; Sakurai, N; Sasou, S; Shibuma, H; Yamauchi, J | 1 |
| Haferlach, C; Kolb, HJ; Schleuning, M; Schwerdtfeger, R; Weisser, M | 1 |
| Guillén, C; Llombart, B; López-Guerrero, JA; Requena, C; Sanmartín, O; Serra, C | 1 |
| Bickenbach, K; Kindler, HL; Noffsinger, A; Posner, MC; Roggin, KK; Veerapong, J; Wilcox, R | 1 |
| Brocca, MC; Coppi, MR; Mele, G; Melpignano, A; Pinna, S; Quarta, G; Romano, A | 1 |
| Joensuu, H | 1 |
| Petersen, JE; Wright, TI | 1 |
| Chatzipanagiotou, T; Papantoniou, V; Pirmettis, I; Ptohis, N; Tsiouris, S | 1 |
| De Pennington, N; Fearnhead, N; Maynard, ND; Sujendran, V; Warren, BF | 1 |
| Choi, EA; Feig, BW | 1 |
| Abrey, LE; Gavrilovic, IT; Lassman, AB; Rosenfeld, SS; Shah, GD; Silver, JS | 1 |
| McArthur, G | 1 |
| Gao, Y; Yang, WL; Yang, XJ; Yu, JR; Zhang, Q | 1 |
| Bergenfeldt, M; Krarup-Hansen, A; Ludvigsen, L; Mahdi, B; Toxvaerd, A | 1 |
| Fujiwara, M; Ishida, T; Kameyama, T; Kuma, S; Matsuyama, A; Okamoto, M; Utsunomiya, T; Yamamoto, M; Yano, S | 1 |
| Astorino, M; Biasco, G; Brandi, G; Castellucci, P; Catena, F; Di Battista, M; Di Scioscio, V; Pantaleo, MA; Piazzi, G; Santini, D; Saponara, M | 1 |
| Fu, Z; Jin, Z; Miao, M; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D | 1 |
| Blay, JY; El Sayadi, H; Garret, J; Ray-Coquard, I; Thiesse, P | 1 |
| Ezumi, K; Ikeda, M; Monden, M; Nomura, M; Sekimoto, M; Takemasa, I; Yamamoto, H | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Deininger, M | 1 |
| Cortes, J; Kantarjian, H | 1 |
| Bensimhon, D; Boudiaf, M; Brouland, JP; Fargeaudou, Y; Rymer, R; Soyer, P | 1 |
| Corless, CL; Demetri, GD; Fisher, DE; Friedlander, P; Heinrich, MC; Hodi, FS; Jagannathan, J; Kruse, A; Mac Rae, S; Van den Abbeele, AD; Velazquez, EF | 1 |
| Choi, H | 1 |
| Van den Abbeele, AD | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, HC; Kim, KH; Kim, TW; Lee, JL; Ryu, MH; Sym, SJ; Yook, JH | 1 |
| Andersson, LC; Capdeville, R; Demetri, GD; Dimitrijevic, S; Druker, B; Joensuu, H; Roberts, PJ; Sarlomo-Rikala, M; Silberman, S; Tervahartiala, P; Tuveson, D | 1 |
| Sawyers, CL | 1 |
| Gschaidmeier, H; Hoelzer, D; Klein, SA; Martin, H; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B | 1 |
| Apperley, JF; Craddock, C; Dazzi, F; Goldman, JM; Marin, D; Marktel, S; Olavarria, E | 1 |
| Blanke, CD; Eisenberg, BL; Heinrich, MC | 1 |
68 review(s) available for imatinib mesylate and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review.
Topics: Anal Canal; Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2022 |
Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Stomach Neoplasms | 2023 |
Chordoma: A Case Report and Review of Literature.
Topics: Afatinib; Aged; Antineoplastic Agents; Chordoma; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hoarseness; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Spinal Neoplasms | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand.
Topics: Chemotherapy, Adjuvant; Gene Expression; Giant Cell Tumor of Tendon Sheath; Hand; Humans; Imatinib Mesylate; Macrophage Colony-Stimulating Factor; Neoplasm Recurrence, Local; Orthopedic Procedures; Treatment Outcome | 2020 |
The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local | 2020 |
Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Neoplasm Recurrence, Local; T-Lymphocytes; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
Disease-free Interval Is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor.
Topics: Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Metastasectomy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2021 |
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
Topics: Aged; Antineoplastic Agents; Drug Substitution; Feasibility Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2017 |
Long-Term Imatinib Treatment for Patients with Unresectable or Recurrent Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Long-Term Care; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Chordoma: a case series and review of the literature.
Topics: Adult; Aged; Bone Neoplasms; Chordoma; Cranial Fossa, Posterior; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sacrum; Skull Base Neoplasms; Spinal Neoplasms; Sunitinib | 2018 |
Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors.
Topics: Anal Canal; Antineoplastic Agents; Digestive System Surgical Procedures; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organ Sparing Treatments; Receptor, Platelet-Derived Growth Factor alpha; Rectal Neoplasms; Risk; Time Factors; Treatment Outcome | 2019 |
Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers.
Topics: Chemotherapy, Adjuvant; Continuity of Patient Care; Contrast Media; Diagnostic Imaging; Drug Resistance, Neoplasm; Early Diagnosis; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protein Kinase Inhibitors; Risk Assessment | 2019 |
Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2013 |
Reintroduction of imatinib in GIST.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Salvage Therapy | 2013 |
New fronts in the adjuvant treatment of GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Risk Factors; Survival Rate; Time Factors | 2013 |
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
Topics: Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Gastrointestinal stromal tumors: who should get imatinib and for how long?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Resistance; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2014 |
Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed | 2015 |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyridines | 2016 |
Recurrent retroperitoneal extra-GIST with rhabdomyosarcomatous and chondrosarcomatous differentiations: a rare case and literature review.
Topics: Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Retroperitoneal Neoplasms | 2015 |
A lethal mesenteric gastrointestinal stromal tumor: a case report and review of the literature.
Topics: Antineoplastic Agents; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mesentery; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms | 2015 |
Combined Therapy of Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Management; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2016 |
[Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Survival Rate | 2008 |
Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rectal Neoplasms | 2008 |
[Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Emergencies; Fatal Outcome; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2008 |
Multidisciplinary treatment of gastrointestinal stromal tumors.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Catheter Ablation; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Mutation; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Survival Analysis | 2009 |
Current treatment options in dermatofibrosarcoma protuberans.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Immunohistochemistry; Microsurgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Skin Neoplasms | 2009 |
Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome; Young Adult | 2009 |
[GIST: adjuvant treatment in Austria].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Imatinib Mesylate; Long-Term Care; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Randomized Controlled Trials as Topic | 2009 |
Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Piperazines; Predictive Value of Tests; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Extragastrointestinal stromal tumors of the omentum: review apropos of a case with a novel gain-of-function KIT mutation.
Topics: Aged; Antineoplastic Agents; Base Sequence; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidental Findings; Male; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Omentum; Peritoneal Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Gastrointestinal stromal tumors: current management.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2010 |
Gastrointestinal stromal tumors (GISTs): an updated experience.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Diagnosis, Differential; Disease Progression; Endoscopy, Gastrointestinal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Living Donors; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rectal Neoplasms; Time Factors; Treatment Outcome; Vaginal Neoplasms | 2010 |
Adjuvant and neoadjuvant therapy for primary GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
The role of imatinib plasma level testing in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Pharmacogenetics; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Comparative Genomic Hybridization; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Molecular Biology; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms; Vaginal Neoplasms | 2011 |
Current and emerging pharmacological treatments for gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Drugs, Investigational; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib | 2011 |
Management of recurrent gastrointestinal stromal tumors.
Topics: Benzamides; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Risk Factors; Rupture; Survival Rate | 2012 |
Malignant perivascular epithelioid cell tumor in children: description of a case and review of the literature.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Child, Preschool; Combined Modality Therapy; Diagnostic Errors; Etoposide; Female; Humans; Imatinib Mesylate; Intestinal Obstruction; Ligaments; Liver Neoplasms; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Perivascular Epithelioid Cell Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Sarcoma, Clear Cell; Sirolimus; X Chromosome Inactivation | 2012 |
Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mitotic Index; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Rupture, Spontaneous | 2012 |
A multidisciplinary approach to giant cell tumors of tendon sheath and synovium--a critical appraisal of literature and treatment proposal.
Topics: Adult; Antineoplastic Agents; Arthroplasty; Arthroscopy; Benzamides; Chemotherapy, Adjuvant; Female; Giant Cell Tumors; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Radioisotopes; Radiotherapy, Adjuvant; Sunitinib; Synovectomy; Synovial Membrane; Tendons; Tenosynovitis | 2013 |
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Skin Neoplasms; Translocation, Genetic | 2013 |
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Stromal Cells; Tomography, Emission-Computed | 2002 |
Gastrointestinal stromal tumors--a review.
Topics: Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Stromal Cells | 2004 |
[Gastrointestinal stromal tumors (GIST)--current concepts of surgical management].
Topics: Benzamides; Chemotherapy, Adjuvant; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Leiomyoma, Epithelioid; Leiomyosarcoma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neurilemmoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors | 2004 |
Recurrent GI bleeding and surgery following the initial response to imatinib therapy in GIST of the stomach.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed | 2005 |
Imatinib mesylate and its potential implications for gynecologic cancers.
Topics: Benzamides; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Imatinib Mesylate; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome; Uterine Neoplasms | 2005 |
Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature.
Topics: Adolescent; Adult; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Molecular Sequence Data; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sequence Homology, Amino Acid | 2005 |
Gastrointestinal stromal tumors and the evolution of targeted therapy.
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2005 |
Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Topics: Adult; Aged; Antineoplastic Agents; Aortic Aneurysm, Abdominal; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tomography, X-Ray Computed | 2006 |
Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Middle Aged; Models, Genetic; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin Neoplasms; Treatment Outcome | 2006 |
Gastrointestinal stromal tumors: imatinib and beyond.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2006 |
[Dermatofibrosarcoma protuberans].
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Combined Modality Therapy; Dermatofibrosarcoma; Drug Design; Humans; Imatinib Mesylate; Mohs Surgery; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Ring Chromosomes; Sarcoma; Skin Neoplasms; Translocation, Genetic | 2007 |
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Phenotype; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms | 2007 |
Second line therapies for the treatment of gastrointestinal stromal tumor.
Topics: Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2007 |
Surgical resection in metastatic gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2007 |
Dermatofibrosarcoma protuberans: recent clinical progress.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Clinical Trials as Topic; Combined Modality Therapy; Dermatofibrosarcoma; Dermatologic Surgical Procedures; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Skin; Skin Neoplasms; Translocation, Genetic | 2007 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Resistance and relapse with imatinib in CML: causes and consequences.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
[Gastrointestinal stromal tumors: role of computed tomography before and after treatment].
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Response evaluation of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Topics: Benzamides; Contrast Media; Disease Progression; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Pyrimidines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Enzyme Inhibitors; Epidemiologic Methods; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunotherapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2001 |
78 trial(s) available for imatinib mesylate and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Safety; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Salvage Therapy; Sunitinib; Treatment Outcome | 2019 |
Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Digestive System Surgical Procedures; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Quality of Health Care; Quality of Life; Survival Rate | 2019 |
Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Prognosis; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
Topics: Antineoplastic Agents; Exanthema; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Steroids; Treatment Outcome | 2020 |
Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Young Adult | 2020 |
A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Young Adult | 2021 |
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sar
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Italy; Neoplasm Recurrence, Local; Sarcoma | 2021 |
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sunitinib | 2021 |
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Risk Factors; Tumor Suppressor Protein p53; Young Adult | 2018 |
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Incidence; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Non-Randomized Controlled Trials as Topic; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sunitinib; Survival Rate | 2019 |
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
Topics: Antineoplastic Agents; Astrocytoma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Prognosis; Survival Rate; Tissue Distribution | 2019 |
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chronic Disease; Female; Gene Amplification; GTP Phosphohydrolases; Humans; Imatinib Mesylate; Male; Melanoma; Membrane Proteins; Middle Aged; Mucous Membrane; Mutation; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Sunlight; Survival Rate | 2013 |
Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Male; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Netherlands; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Survival Analysis | 2013 |
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
Topics: Belgium; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Neoplasm Recurrence, Local; Netherlands; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome | 2013 |
Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Pyrimidines; Treatment Outcome | 2013 |
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Patient Selection; Phenotype; Piperazines; Precision Medicine; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Young Adult | 2014 |
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk Factors | 2014 |
Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Patient Selection; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sample Size; Time Factors; Treatment Outcome | 2014 |
Outcome after HSCT in Philadelphia chromosome positive acute lymphoblastic leukemia in Sweden: a population-based study.
Topics: Adult; Aged; Autografts; Benzamides; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Sweden; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Benzamides; Central Nervous System; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2014 |
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Topics: Aged; Benzamides; Biomarkers; Biomarkers, Tumor; Disease-Free Survival; Humans; Hydroxamic Acids; Imatinib Mesylate; Kinetics; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrimidines | 2015 |
Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Tr
Topics: Adult; Aged; Aged, 80 and over; Australasia; Chemotherapy, Adjuvant; Disease-Free Survival; European Union; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Cooperation; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Odds Ratio; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salvage Therapy; Treatment Failure | 2015 |
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2016 |
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Topics: Abdominal Wall; Antineoplastic Agents; Biopsy, Needle; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasm Seeding; Protein Kinase Inhibitors; Risk Factors; Tomography, X-Ray Computed | 2016 |
Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Probability; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioma; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Statistics, Nonparametric; Treatment Outcome | 2008 |
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2009 |
Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma.
Topics: Antineoplastic Agents; Benzamides; Child, Preschool; Female; Glioma; Humans; Hypothalamic Neoplasms; Imatinib Mesylate; Immunohistochemistry; Infant; Male; Neoplasm Recurrence, Local; Optic Chiasm; Optic Nerve Glioma; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission.
Topics: Administration, Oral; Adult; Aged; Benzamides; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL T
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2009 |
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Canada; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Temozolomide; Treatment Outcome; Young Adult | 2010 |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2009 |
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinosarcoma; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Uterine Neoplasms | 2010 |
Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Outcome | 2009 |
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Everolimus; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome | 2010 |
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylation; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2011 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy | 2010 |
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Adenoid Cystic; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography, Thoracic; Radiopharmaceuticals; Remission Induction; Salivary Gland Neoplasms; Survival Rate; Tomography, X-Ray Computed; Young Adult | 2011 |
Surgical outcomes of gastrointestinal stromal tumors of the stomach: a single unit experience in the era of targeted drug therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2012 |
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Taxoids | 2012 |
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Topics: Adult; Benzamides; CD3 Complex; CD56 Antigen; Cytokine-Induced Killer Cells; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines | 2012 |
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Infant; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Stem Cell Transplantation; Survival Rate | 2012 |
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Exons; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Proto-Oncogene Proteins c-kit; Pyrimidines; Republic of Korea; Treatment Outcome | 2013 |
Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Bone Marrow Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Longitudinal Studies; Male; Neoplasm Recurrence, Local; Neuroblastoma; Piperazines; Pyrimidines; RNA, Messenger; Tyrosine 3-Monooxygenase | 2013 |
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA Mutational Analysis; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2002 |
[Morphology of gastrointestinal stromal tumors in advanced stages of the disease: baseline findings before chemotherapy with imatinib].
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Contrast Media; Digestive System; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Image Enhancement; Imatinib Mesylate; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Mesothelial; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2003 |
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Fusion Proteins, bcr-abl; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2003 |
Phase II study of imatinib in patients with small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2003 |
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; False Positive Reactions; Female; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Radiography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Stromal Cells; Tomography, Emission-Computed; Treatment Outcome | 2004 |
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nucleic Acid Hybridization; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Safety; Time Factors; Tomography, X-Ray Computed | 2005 |
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Edema; Fatigue; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Failure | 2005 |
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Salvage Therapy; Survival Rate | 2005 |
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Piperazines; Pyrimidines; Taxoids | 2006 |
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure | 2006 |
Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography.
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phospholipids; Piperazines; Polysaccharides; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sulfur Hexafluoride; Ultrasonography, Doppler | 2006 |
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Care Planning; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Treatment Outcome | 2006 |
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Central Nervous System Neoplasms; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2007 |
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial | 2008 |
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Synthesis Inhibitors; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2007 |
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Premedication; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
275 other study(ies) available for imatinib mesylate and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Definition of tumor rupture in gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rupture, Spontaneous | 2021 |
[Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local | 2021 |
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Chemotherapy, Adjuvant; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Retrospective Studies | 2022 |
CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Imatinib Mesylate; Mice; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured | 2021 |
Successful Endoscopic Resection of a Rectal Gastrointestinal Stromal Tumor Larger Than 5 cm.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2021 |
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
Impact of preoperative tumor rupture timing on gastrointestinal stromal tumor prognosis: a retrospective multicentric cohort study.
Topics: Antineoplastic Agents; Cohort Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2022 |
[Long-Term Survival by Low-Dose Imatinib after Recurrence of GIST].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2022 |
Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
The nerve-tumour regulatory axis GDNF-GFRA1 promotes tumour dormancy, imatinib resistance and local recurrence of gastrointestinal stromal tumours by achieving autophagic flux.
Topics: Antineoplastic Agents; Autophagy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prospective Studies | 2022 |
Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Nomograms; Retrospective Studies; Risk Factors | 2022 |
The role of neoadjuvant imatinib in gastrointestinal stromal tumor patients: 20 years of experience from a tertial referral center.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Referral and Consultation; Retrospective Studies | 2022 |
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Stomach Neoplasms | 2022 |
Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines | 2022 |
From Morphea to Dermatofibrosarcoma Protuberans.
Topics: Adult; Cicatrix; Dermatofibrosarcoma; Disease Progression; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Scleroderma, Localized; Skin Neoplasms; Young Adult | 2022 |
Oncological efficiency of wide local excision in dermatofibrosarcoma protuberans.
Topics: Dermatofibrosarcoma; Follow-Up Studies; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies; Skin Neoplasms | 2023 |
Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit | 2023 |
[A Case of GIST of Stomach with Peritoneal Dissemination-Long-Term Survival with Imatinib and Surgical Resection].
Topics: Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Stomach | 2022 |
Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST).
Topics: Cell-Free Nucleic Acids; Circulating Tumor DNA; DNA; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Receptor Protein-Tyrosine Kinases | 2023 |
Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.
Topics: Antineoplastic Agents; Cohort Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Registries; Retrospective Studies | 2023 |
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases.
Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphomatoid Papulosis; Male; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Transcription Factors | 2023 |
Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential.
Topics: Antineoplastic Agents; Cell Cycle; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Recurrence | 2023 |
Perspectives of Patients With Dermatofibrosarcoma Protuberans on Diagnostic Delays, Surgical Outcomes, and Nonprotuberance.
Topics: Adult; Delayed Diagnosis; Dermatofibrosarcoma; Diagnostic Errors; Female; Humans; Imatinib Mesylate; Interdisciplinary Placement; Male; Middle Aged; Mohs Surgery; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Radiotherapy; Risk Assessment; Self-Help Groups; Skin Neoplasms; Social Media; Surveys and Questionnaires; Treatment Outcome | 2019 |
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Polymerase Chain Reaction | 2019 |
Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Diagnosis, Differential; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Humans; Ileum; Imatinib Mesylate; Jejunum; Laparoscopy; Length of Stay; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors | 2020 |
Long-Term Survival After Multidisciplinary Treatment Including Surgery for Metachronous Metastases of Small Intestinal Gastrointestinal Stromal Tumors after Curative Resection: A Case Report.
Topics: Bone Neoplasms; Combined Modality Therapy; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Sunitinib | 2019 |
Recurrence-free Survival and Safety of Imatinib in Patients With Gastrointestinal Stromal Tumour (GIST) in Greece.
Topics: Disease-Free Survival; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Greece; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome | 2020 |
Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Records; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
[A Case of Gastrointestinal Stromal Tumor in the Rectum with Preservation of Anal Function after Neoadjuvant Chemotherapy UsingImatinib].
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2019 |
[A Case of Omental Desmoid Tumor after a Small Bowel Resection for Gastrointestinal Stromal Tumor].
Topics: Aged; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Omentum | 2019 |
[A Case of Gastrointestinal Stromal Tumor Re-Resected Ten Years after the Resection of Its Recurrence].
Topics: Aged; Angiomyolipoma; Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2019 |
Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Topics: Adult; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2020 |
Tumor-associated tertiary lymphoid structure predicts postoperative outcomes in patients with primary gastrointestinal stromal tumors.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Tertiary Lymphoid Structures | 2020 |
Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story.
Topics: Child Development; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome; Withholding Treatment | 2020 |
[Gastric Gastrointestinal Stromal Tumor Appearing Nine Years after Resection of a Duodenal Gastrointestinal Stromal Tumor-A Case Report].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms | 2020 |
[A Case of Multidisciplinary Treatment for a Recurrent Gastrointestinal Stromal Tumor of the Stomach].
Topics: Aged; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Stomach | 2020 |
Prolapsed giant rectal gastrointestinal stromal tumor presented with incarceration A rare case of emergency rectal lesion.
Topics: Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Prolapse; Rectum | 2020 |
Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Clinical Decision-Making; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Mucosa; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Nomograms; Predictive Value of Tests; Proctectomy; Rectal Neoplasms; Rectum; Retrospective Studies; Risk Assessment; Risk Factors | 2020 |
[Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Cytoreduction Surgical Procedures; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Patient Care Team; Sunitinib; Treatment Outcome; Tumor Burden | 2020 |
[Research advance of liquid biopsy in gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Early Detection of Cancer; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liquid Biopsy; Neoplasm Recurrence, Local | 2020 |
The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
Topics: Adult; Aged; Antineoplastic Agents; England; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Retrospective Studies; Treatment Outcome | 2020 |
Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance.
Topics: Adult; Aged; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Microsurgery; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome | 2021 |
Minimally Invasive Resection of Large Gastric Gastrointestinal Stromal Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Conversion to Open Surgery; Disease-Free Survival; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intraoperative Complications; Laparoscopy; Length of Stay; Male; Margins of Excision; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tumor Burden | 2020 |
Solitary peritoneal metastasis of gastrointestinal stromal tumor: A case report.
Topics: Aged; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Peritoneum | 2020 |
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient.
Topics: Abdomen; Aged, 80 and over; Endoscopy, Gastrointestinal; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Tomography, X-Ray Computed | 2020 |
[Preoperative Imatinib Therapy Followed by Laparoscopic Local Gastrectomy for a Giant Gastric Gastrointestinal Stromal Tumor-A Case Report].
Topics: Antineoplastic Agents; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms | 2020 |
Imatinib and nutritional support can make successful treatment for a case of huge liver metastasis of duodenal gastrointestinal stromal tumor that initially showed jaundice and cachexia.
Topics: Adult; Antineoplastic Agents; Cachexia; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jaundice; Liver Neoplasms; Neoplasm Recurrence, Local; Nutritional Support | 2021 |
[A Case of Gastrointestinal Stromal Tumor of the Lower Rectum That Enabled Minimally Invasive Surgery with Imatinib Mesylate as Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms; Rectum | 2021 |
Duodenal perforation caused by imatinib mesylate during adjuvant treatment of gastric stromal tumor: Case report.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2021 |
[A Case of the Large Rectal GIST Treated by Laparoscopic Anus Preserving Operation after Neoadjuvant Therapy with Imatinib Mesylate].
Topics: Anal Canal; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2021 |
LncRNA-HOTAIR activates autophagy and promotes the imatinib resistance of gastrointestinal stromal tumor cells through a mechanism involving the miR-130a/ATG2B pathway.
Topics: Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cell Proliferation; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; MicroRNAs; Neoplasm Recurrence, Local; RNA, Long Noncoding; Vesicular Transport Proteins | 2021 |
National Utilization of Imatinib in the Management of Resected Gastrointestinal Stromal Tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Middle Aged; Neoplasm Recurrence, Local | 2021 |
Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Rectal Neoplasms; Retrospective Studies | 2021 |
Humeral metastasis as the only recurrence of a 5-year resected gastrointestinal stromal tumor: a case report.
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Humerus; Imatinib Mesylate; Liver Neoplasms; Neoplasm Recurrence, Local | 2021 |
A Novel Curative Treatment Strategy for Patients with Lower Grade Rectal Gastrointestinal Stromal Tumor: Chemoreduction Combined with Transanal Endoscopic Microsurgery.
Topics: Adult; Aged; Antineoplastic Agents; China; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Postoperative Complications; Rectal Neoplasms; Retrospective Studies; Transanal Endoscopic Microsurgery; Treatment Outcome | 2017 |
Breast and pleuropulmonary metastasis of multirecurrent scalp dermatofibrosarcoma protuberans: a case report.
Topics: Adult; Alopecia; Antigens, CD34; Antineoplastic Agents; Biopsy; Breast Neoplasms; Cough; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Recurrence, Local; Pleural Neoplasms; Prognosis; Scalp; Skin Neoplasms; Treatment Outcome | 2017 |
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate | 2017 |
Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Data Interpretation, Statistical; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Perioperative Care; Prognosis; Rectal Neoplasms; Registries | 2017 |
Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Endosonography; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Female; Follow-Up Studies; France; Gastrointestinal Stromal Tumors; Humans; Image-Guided Biopsy; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Practice Patterns, Physicians'; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
[Gastrointestinal stromal tumor and renal transplant].
Topics: Anoctamin-1; Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Transplantation; Neoplasm Proteins; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Young Adult | 2017 |
[Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Databases, Factual; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Young Adult | 2017 |
Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medical Oncology; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organ Preservation; Prognosis; Prospective Studies; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2017 |
Gastric Gastrointestinal Stromal Tumors (GIST): a Case Series and Current State of the Art in the Workup and Treatment of This Rare Disease.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Rare Diseases; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2019 |
Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; Drug Resistance, Neoplasm; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Transplantation, Heterologous; Tumor Cells, Cultured | 2018 |
[Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma].
Topics: Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Combined Modality Therapy; Contraindications, Procedure; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Paraplegia; Radiotherapy, Adjuvant; Sacrococcygeal Region; Skin Neoplasms; Skin Ulcer; Soft Tissue Neoplasms | 2018 |
Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Survival Rate | 2018 |
Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Area Under Curve; Chemotherapy, Adjuvant; Cohort Studies; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Young Adult | 2018 |
Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.
Topics: Adolescent; Antineoplastic Agents; Down Syndrome; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl | 2019 |
Cost-Effectiveness of Carbon Ion Radiation Therapy for Skull Base Chordoma Utilizing Long-Term (10-Year) Outcome Data.
Topics: Antineoplastic Agents; Chordoma; Cost-Benefit Analysis; Disease-Free Survival; Health Care Costs; Heavy Ion Radiotherapy; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Skull Base; Skull Base Neoplasms | 2018 |
Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib: A case report.
Topics: Antineoplastic Agents; Chromosomes, Human, 16-18; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Neoplasm Recurrence, Local; Philadelphia Chromosome; Pyrimidines; Translocation, Genetic | 2018 |
[Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha | 2018 |
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Adult; Aged; Databases, Factual; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Norway; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rupture; Survival Analysis; Treatment Outcome | 2019 |
Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.
Topics: Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyridazines; Recurrence | 2018 |
Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report.
Topics: Adult; Female; Granulosa Cell Tumor; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Precision Medicine; Treatment Outcome | 2019 |
Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cancer Survivors; Cohort Studies; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local | 2019 |
[Hepatic and Pancreatic Metastases of a Rectal Gastrointestinal Stromal Tumor in a Patient with Long-Term Survival following Combined Therapy-ACase Report].
Topics: Aged; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2019 |
Author response to comment on: Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines | 2019 |
Comment on: Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines | 2019 |
Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; International Agencies; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Rectal Neoplasms; Registries; Retrospective Studies; Survival Rate | 2019 |
Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach.
Topics: Anus Neoplasms; Base Sequence; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiography; Rectal Neoplasms; Reference Standards; Retrospective Studies; Treatment Outcome | 2013 |
Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
Topics: Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Neoplasms; Treatment Outcome | 2013 |
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria.
Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib | 2013 |
[Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
Topics: Adult; Aged; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2013 |
NCCN Task Force report: gastrointestinal stromal tumor (GIST).
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2004 |
[Prognostic analysis of 349 cases with gastrointestinal stromal tumor].
Topics: Benzamides; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Postoperative Period; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis | 2013 |
Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Exons; Female; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Neoplasm Recurrence, Local; Pedigree; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Young Adult | 2013 |
Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors.
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.
Topics: Benzamides; CD8-Positive T-Lymphocytes; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome; Up-Regulation | 2013 |
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Databases, Factual; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2013 |
Spontaneous hemoperitoneum in recurrent jejunal gastrointestinal stromal tumor after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Jejunum; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2013 |
Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
Topics: Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
[Clinical analysis of efficacy and prognosis of intermediate risk gastric stromal tumor patients].
Topics: Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Diagnostic Errors; Digestive System Surgical Procedures; Duodenal Neoplasms; Fibromatosis, Abdominal; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Jejunal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Predictive Value of Tests; Pyrimidines; Reoperation; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Unnecessary Procedures | 2013 |
Presentation and management of gastrointestinal stromal tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopes; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzamides; Biomarkers, Tumor; Case-Control Studies; Docetaxel; Electrophoresis, Microchip; Female; Glycoproteins; Glycosylation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperazines; Polysaccharides; Principal Component Analysis; Protein Processing, Post-Translational; Pyrimidines; ROC Curve; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Taxoids | 2013 |
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Diagnostic Techniques and Procedures; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2013 |
The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Survival Rate | 2013 |
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2014 |
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Benzamides; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Homologous; Young Adult | 2014 |
[A rare case of bone metastasis from gastro-intestinal stromal tumour: place of radiotherapy].
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Femoral Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Humerus; Imatinib Mesylate; Ischium; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Pain Management; Peritoneal Neoplasms; Piperazines; Pubic Bone; Pyrimidines; Stomach Neoplasms | 2014 |
Src activity is increased in gastrointestinal stromal tumors--analysis of associations with clinical and other molecular tumor characteristics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Vascular Endothelial Growth Factor A | 2014 |
Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptor, EphB4; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2014 |
Ph+ ALL: imatinib grows older with patients.
Topics: Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2014 |
Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
[A multicentre retrospective cohort study of patients with gastrointestinal stromal tumors in Shandong Province].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2014 |
[Clinicopathological analysis of 61 patients with rectal gastrointestinal stromal tumors].
Topics: Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Rectal Neoplasms; Retrospective Studies; Survival Rate | 2014 |
[Efficacy and prognosis of different treatments on 63 patients with small intestinal gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2014 |
A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2014 |
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Treatment Outcome | 2014 |
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mitotic Index; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Risk Factors; Treatment Outcome | 2014 |
The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Propensity Score; Pyrimidines; Retrospective Studies; Survival Rate; Young Adult | 2014 |
A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum.
Topics: Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease Progression; Dissection; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hemoperitoneum; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Postoperative Complications; Pyrimidines; Risk Assessment; Rupture, Spontaneous | 2015 |
Intra-abdominal desmoid tumor after resection for gastrointestinal stromal tumor of the small intestine: case report.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Fibromatosis, Abdominal; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rare Diseases | 2014 |
A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies | 2014 |
Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient.
Topics: Antineoplastic Agents; Benzamides; Child, Preschool; Eosinophilia; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Withholding Treatment | 2014 |
KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Cell Transdifferentiation; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2015 |
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Health Services; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local | 2015 |
Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report.
Topics: Adult; Antineoplastic Agents; Benzamides; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Longitudinal Studies; Male; Muscle Neoplasms; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rotator Cuff | 2014 |
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Preoperative Care; Preoperative Period; Pyrimidines; Reproducibility of Results; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2014 |
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Metastasectomy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2015 |
[Clinicopathological analysis of 80 patients with duodenum gastrointestinal stromal tumors].
Topics: Abdominal Pain; Benzamides; Duodenal Neoplasms; Female; Gastrointestinal Hemorrhage; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreaticoduodenectomy; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate | 2015 |
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Recombinant Proteins; Remission Induction; Survival Rate; Young Adult | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Human; Cyclin-Dependent Kinase 4; Dacarbazine; Disease Progression; Fatal Outcome; Female; Genetic Association Studies; Genetic Predisposition to Disease; Glioblastoma; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neurosurgical Procedures; Phenotype; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Temozolomide; Time Factors; Treatment Outcome | 2015 |
PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
Topics: Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Phosphorylation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Signal Transduction; Survival Rate; TOR Serine-Threonine Kinases | 2015 |
Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Tumor Suppressor Protein p53; Young Adult | 2015 |
Gastrointestinal stromal tumour in a recipient with kidney transplantation.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Transplantation; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2015 |
Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Retrospective Studies; Severity of Illness Index; Survival Analysis; Time Factors | 2015 |
Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Survival Rate | 2015 |
The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asia; Biomarkers, Tumor; Canada; Digestive System Surgical Procedures; Disease Progression; DNA Mutational Analysis; Europe; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Registries; Risk Factors; South America; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2015 |
Imatinib in advanced chordoma: A retrospective case series analysis.
Topics: Aged; Antineoplastic Agents; Chordoma; Compassionate Use Trials; Disease-Free Survival; Edema; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-sis; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Treatment Outcome | 2015 |
Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Risk; Time Factors | 2016 |
Risk Classification using the Ki-67 Labeling Index for Surgically-Treated Gastric Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Mitotic Index; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Tumor Burden | 2015 |
Imatinib Inhibits the Renewal and Tumorigenicity of CT-26 Colon Cancer Cells after Cytoreductive Treatment with Doxorubicin.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Hypoxia; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oxygen; Real-Time Polymerase Chain Reaction; Signal Transduction | 2017 |
Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study.
Topics: Anoctamin-1; Antineoplastic Agents; Biomarkers, Tumor; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prognosis; Prospective Studies | 2016 |
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Protein Kinase Inhibitors; Remission Induction | 2016 |
Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Registries; Retrospective Studies; Survival Rate; Time Factors | 2017 |
Evaluation of Gold's nomogram for predicting recurrence-free survival in gastrointestinal stromal tumors in Indian patients.
Topics: Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; India; Neoplasm Recurrence, Local; Probability; Retrospective Studies; Risk; Time Factors; Validation Studies as Topic | 2016 |
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
[Lancet in the era of targeted drug therapy: the role of surgery in the management of advanced gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Pyrimidines | 2016 |
[Preliminary understanding of gastrointestinal stromal tumor with the highest risk].
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Risk | 2016 |
[Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; China; Combined Modality Therapy; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2016 |
[Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies | 2016 |
[Treatment and prognosis of 108 patients with high-risk gastrointestinal stromal tumor].
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; China; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2017 |
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Salvage Therapy | 2017 |
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Dasatinib; Deprescriptions; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Protein Kinase Inhibitors; Quinolines; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Watchful Waiting; Young Adult | 2017 |
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Transplantation Chimera; Transplantation, Homologous | 2008 |
Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Scalp; Skin Neoplasms | 2008 |
Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Perforation; Male; Neoplasm Recurrence, Local; Peritonitis; Piperazines; Pyrimidines; Pyrroles; Sunitinib | 2008 |
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Diagnostic Imaging; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
'Time is a GIFT in GIST'--the medical and paramedical perspective of a case with metastatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Muscle Tissue; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed | 2009 |
Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Cisplatin; Female; Fluorescent Antibody Technique; Fluorouracil; Humans; Imatinib Mesylate; In Vitro Techniques; Neoplasm Recurrence, Local; Piperazines; Pneumonectomy; Pyrimidines; Radiotherapy; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumor, Pleural | 2009 |
Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.
Topics: Aged; Benzamides; Gastrointestinal Stromal Tumors; Humans; Hypopigmentation; Imatinib Mesylate; Male; Melanins; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Vitiligo | 2008 |
[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Early Detection of Cancer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Surgical resection of esophageal gastrointestinal stromal tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Deglutition Disorders; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Thoracotomy; Treatment Outcome | 2009 |
Invited commentary.
Topics: Antineoplastic Agents; Benzamides; Esophageal Neoplasms; Esophagectomy; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Time Factors | 2009 |
Repeated surgery improves survival in recurrent gastrointestinal stromal tumors: a retrospective analysis of 144 patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Protocols; Combined Modality Therapy; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leiomyoma; Leiomyosarcoma; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Neurilemmoma; Piperazines; Pyrimidines; Reoperation; Retrospective Studies; Treatment Outcome | 2009 |
[A case of recurrent gastrointestinal stromal tumor of the stomach with complete response to imatinib mesilate].
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Remission Induction; Stomach Neoplasms | 2009 |
Primary large gastrointestinal stromal tumor of the liver: report of a case.
Topics: Adult; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Skin Neoplasms; Stomach Neoplasms | 2009 |
Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm, Residual; Peptide Fragments; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Splenic Neoplasms; Tomography, X-Ray Computed | 2009 |
[Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dermatofibrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Skin Neoplasms | 2009 |
Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Transplantation, Homologous; Treatment Outcome | 2009 |
[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Codon; Drug Resistance, Neoplasm; Exons; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2009 |
Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.
Topics: Aged, 80 and over; Benzamides; Biopsy, Needle; Combined Modality Therapy; Down-Regulation; Drug Resistance, Neoplasm; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Long-term survival after surgery and adjuvant imatinib in a patient with rectal GIST, local recurrence, liver metastases and mediastinal pleural metastasis].
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mediastinum; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pleural Neoplasms; Pyrimidines; Rectal Neoplasms | 2009 |
Managing relapse of CML using therapeutic imatinib plasma level.
Topics: Benzamides; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
[Carney triad: clinicopathologic study of 2 cases with molecular analysis].
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Benzamides; Chondroma; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Piperazines; Pneumonectomy; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome | 2010 |
Primary thoracic cavity gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Thoracic Neoplasms; Thoracotomy; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome | 2010 |
Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation.
Topics: Anoctamin-1; Antineoplastic Agents; Atrial Fibrillation; Benzamides; Chloride Channels; Depression; Gastrointestinal Stromal Tumors; Humans; Hypercholesterolemia; Hypertension; Imatinib Mesylate; Immunohistochemistry; Male; Membrane Proteins; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Piperazines; Pleural Neoplasms; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Stem Cell Transplantation; Young Adult | 2010 |
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2010 |
Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Case-Control Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leiomyoma; Male; Middle Aged; Midkine; Neoplasm Recurrence, Local; Neoplasm Staging; Nerve Growth Factors; Piperazines; Prognosis; Pyrimidines; Survival Rate; Tissue Array Analysis | 2011 |
Emergence of secondary resistance to imatinib in recurrent gastric GIST.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Stomach Neoplasms | 2010 |
Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Health Care Costs; Humans; Imatinib Mesylate; Markov Chains; Models, Economic; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors | 2010 |
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Radiography; Sunitinib | 2011 |
[The giant gastrointestinal tumor of the stomach].
Topics: Abdominal Pain; Aged; Antineoplastic Agents; Benzamides; Duodenum; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Mitotic Index; Neoplasm Recurrence, Local; Patient Care Planning; Piperazines; Preoperative Care; Pyrimidines; Radiography; Risk Assessment; Stomach; Treatment Outcome | 2011 |
Female adnexal tumor of probable Wolffian origin (FATWO) with recurrence 3 years postsurgery.
Topics: Adenoma; Adnexal Diseases; Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Broad Ligament; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Ovarian Neoplasms; Piperazines; Polymerase Chain Reaction; Pyrimidines; Selective Estrogen Receptor Modulators; Tamoxifen | 2011 |
Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Survival | 2011 |
NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Nuclear Pore Complex Proteins; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl; Pyrimidines; Salvage Therapy; Treatment Outcome | 2011 |
Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
Topics: Adolescent; Adult; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Small-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variant.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2011 |
Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: report of a case.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Neoplasms, Multiple Primary; Piperazines; Pyrimidines | 2011 |
Third-line chemotherapy with tyrosine kinase inhibitor (imatinib mesylate) in recurrent ovarian granulosa cell tumor: case report.
Topics: Antineoplastic Agents; Benzamides; Female; Granulosa Cell Tumor; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2011 |
[Clinical analysis of 79 gastrointestinal tract stromal tumor cases].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2011 |
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Exons; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Survival Rate; Young Adult | 2012 |
The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.
Topics: Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Benzamides; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult | 2012 |
Right axillosubclavian vein thrombosis resolved by percutaneous rheolytic thrombectomy in a patient with a recurrent gastrointestinal stromal tumour undergoing imatinib mesylate treatment.
Topics: Angiography; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Phlebography; Piperazines; Pyrimidines; Subclavian Vein; Thrombectomy; Thrombolytic Therapy; Venous Thrombosis; Warfarin | 2012 |
A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prospective Studies; Pyrimidines; Risk Assessment; Risk Factors; Stomach Neoplasms; Watchful Waiting | 2012 |
FDA updates Gleevec label for GIST patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Labeling; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2012 |
Updates on the management of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pedigree; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Receptor, Platelet-Derived Growth Factor alpha; Risk Assessment | 2012 |
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Topics: Adult; Aged; Benzamides; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors | 2012 |
Aggressive gastrointestinal stromal tumour of the oesophagus with homozygous KIT exon 11 deletion mutation.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Esophageal Neoplasms; Exons; Female; Gastrointestinal Stromal Tumors; Gene Deletion; Homozygote; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2012 |
[Pregnancy and extra-gastrointestinal stromal tumor: an exceptional association].
Topics: Abdominal Neoplasms; Adult; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2012 |
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult | 2012 |
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk Factors; Young Adult | 2012 |
Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intraoperative Complications; Mitotic Index; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Risk; Rupture, Spontaneous | 2012 |
Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rupture; Treatment Outcome | 2012 |
Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neurofibromatosis 1; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk; Tomography, X-Ray Computed | 2012 |
Surgical management of rectal gastrointestinal stromal tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Digestive System Surgical Procedures; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Piperazines; Pyrimidines; Rectal Neoplasms; Retrospective Studies; Treatment Outcome | 2013 |
Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Rectal Neoplasms; Survival Rate | 2013 |
Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible?
Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Remission Induction; Tomography, X-Ray Computed | 2012 |
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors | 2013 |
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Practice Patterns, Physicians'; Pyrimidines; Retrospective Studies; Risk Factors; Time; Treatment Outcome | 2013 |
Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2013 |
Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Patient Selection; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk Assessment; Risk Factors | 2013 |
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Topics: Alleles; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Structure, Tertiary; Pyrimidines; Recurrence; Time Factors | 2002 |
An FDG positron emission tomographic study in a case of gastrointestinal stromal tumor.
Topics: Appendiceal Neoplasms; Benzamides; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Jejunal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2003 |
Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2003 |
Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Monocytic, Acute; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2003 |
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Transplantation, Homologous; Treatment Outcome | 2003 |
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Mitosis; Mortality; Necrosis; Neoplasm Recurrence, Local; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies; Staining and Labeling; Stromal Cells; Tomography, X-Ray Computed | 2003 |
[Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
Topics: Adult; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms; Treatment Outcome | 2003 |
Fibrous dysplasia masquerading as extramedullary relapse after bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Exophthalmos; Female; Fibrous Dysplasia of Bone; Humans; Hyperthyroidism; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Orbital Neoplasms; Piperazines; Pyrimidines | 2003 |
Isolated abdominal wound metastasis from a gastrointestinal stromal tumor.
Topics: Abdominal Wall; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Digestive System Surgical Procedures; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Laparoscopy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Postoperative Complications; Pyrimidines; Stromal Cells; Surgical Wound Dehiscence | 2003 |
[Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cardia; Chemotherapy, Adjuvant; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagectomy; Female; Gastrectomy; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Imatinib Mesylate; Incidental Findings; Male; Neoplasm Recurrence, Local; Neoplasms, Connective Tissue; Piperazines; Polyps; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor Protein-Tyrosine Kinases; Shock, Hemorrhagic; Stomach Neoplasms; Stromal Cells; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Doxorubicin; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Neoplasm Proteins; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Vincristine | 2004 |
Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation.
Topics: Antineoplastic Agents; Benzamides; Connective Tissue Diseases; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunosuppressive Agents; Liver Transplantation; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2004 |
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Banding; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate | 2004 |
Recurrent spinal ependymoma showing partial remission under Imatimib.
Topics: Adult; Antineoplastic Agents; Benzamides; Ependymoma; Female; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Spinal Cord Neoplasms | 2004 |
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cranial Irradiation; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2004 |
Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Mice; Mice, Nude; Neoplasm Recurrence, Local; Nuclear Proteins; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Tumor Cells, Cultured; Tyrphostins | 2004 |
[Two cases of postoperative recurrence of gastric GIST treated by imatinib].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stomach Neoplasms; Thyroid Neoplasms | 2004 |
[Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Edema; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction; Survival Rate | 2004 |
An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Spinal Neoplasms; Treatment Outcome | 2005 |
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Homologous | 2006 |
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2005 |
[Gastrointestinal stromal tumor successfully treated with re-administration of STI571 despite of serious skin rash: a case report].
Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Drug Eruptions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mesentery; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Piperazines; Pyrimidines | 2005 |
[How should patients with completely resected gastrointestinal stromal tumours (GIST) be followed up?].
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Endoscopy, Gastrointestinal; Endosonography; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines | 2005 |
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines; Remission Induction | 2006 |
First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rectal Neoplasms; Rectum; Treatment Outcome; Ultrasonography | 2006 |
Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status.
Topics: Adult; Base Pair Mismatch; Benzamides; Brachial Plexus; Brachial Plexus Neuropathies; Chemotherapy, Adjuvant; Combined Modality Therapy; DNA Mutational Analysis; Exons; Female; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Nervous System Neoplasms; Piperazines; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Pyrimidines; Reoperation | 2006 |
Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Child; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Risk Factors; Statistics, Nonparametric | 2006 |
Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy.
Topics: Adult; Antineoplastic Agents; Benzamides; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survivors | 2006 |
Intracranial recurrence of the scalp dermatofibrosarcoma.
Topics: Adult; Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Sinuses; Dermatofibrosarcoma; Embolization, Therapeutic; Female; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Reoperation; Scalp; Skin Neoplasms; Skull Neoplasms | 2007 |
[A case of recurrent GIST successfully treated with low-dose imatinib mesilate].
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Male; Neoplasm Recurrence, Local; Pelvis; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
[Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Postoperative Period; Prospective Studies; Pyrimidines; Young Adult | 2006 |
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2007 |
Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chordoma; Disease Progression; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sensitivity and Specificity | 2007 |
Hypoglycemia in the setting of advanced gastrointestinal stromal tumor.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Diagnosis, Differential; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Imatinib Mesylate; Leiomyosarcoma; Neoplasm Recurrence, Local; Palliative Care; Paraneoplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Cell Differentiation; DNA, Neoplasm; Endometrial Neoplasms; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma | 2007 |
[A case of recurrent GIST of the esophagus which completely responded to imatinib mesilate].
Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Piperazines; Pyrimidines; Remission Induction; Skin Neoplasms | 2007 |
Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2007 |
What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Male; Meningeal Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiotherapy; Salvage Therapy | 2007 |
Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery.
Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Mohs Surgery; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Scalp; Skin Neoplasms | 2007 |
Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.
Topics: Adult; Antineoplastic Agents; Benzamides; Brain; Brain Neoplasms; Cell Proliferation; Fatal Outcome; Glioblastoma; Humans; Imatinib Mesylate; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Radiopharmaceuticals; Technetium Tc 99m Dimercaptosuccinic Acid; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2007 |
Proposals for the management of gastrointestinal stromal tumours of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Follow-Up Studies; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Piperazines; Population Surveillance; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Splenectomy; Stomach Neoplasms; Thoracic Neoplasms; Thoracic Wall; Treatment Outcome | 2007 |
Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2007 |
Successful resection of an advanced duodenal gastrointestinal stromal tumor after down-staging with imatinib: report of a case.
Topics: Adult; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Dose-Response Relationship, Drug; Duodenal Neoplasms; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreaticoduodenectomy; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2007 |
Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case.
Topics: Aged; Antineoplastic Agents; Benzamides; DNA, Neoplasm; Exons; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Time Factors; Tomography, X-Ray Computed | 2008 |
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2008 |
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Transplantation, Homologous | 2008 |
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
Topics: Adult; Antineoplastic Agents; Benzamides; Elbow Joint; Female; Giant Cell Tumors; Humans; Imatinib Mesylate; Joint Diseases; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Synovitis, Pigmented Villonodular; Treatment Outcome | 2008 |
Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dacarbazine; Doxorubicin; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Male; Mesentery; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction; Tamoxifen | 2008 |
[Consensus on the medical treatment of gastrointestinal stromal tumors].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Major response to imatinib mesylate in KIT-mutated melanoma.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms | 2008 |
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fluorodeoxyglucose F18; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma; Stomach Neoplasms; Stromal Cells; Tomography, Emission-Computed | 2001 |
Cancer treatment in the STI571 era: what will change?
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Evidence-Based Medicine; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Patient Selection; Piperazines; Pyrimidines; Stromal Cells | 2001 |
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; Colitis; Combined Modality Therapy; Enzyme Inhibitors; Female; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Immunosuppression Therapy; Interferon-alpha; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Transfusion; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous | 2001 |
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Transplantation, Homologous | 2002 |